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Adrenomedullin (AM) and pro-adrenomedullin N-terminal 20-peptide (PAMP) 
are peptides recently identified from a rat pheochromocytoma. Both of these 
peptides are cleavage products of pre-pro-AM. Specific receptors for AM have 
been characterised in several species, including rat and human. The aim of this 
study was to investigate the role of PAMP and AM in the adrenal cortex. 
Using an intact rat capsule preparation PAMP was shown to cause a dose- 
dependent increase in aldosterone secretion, which was accompanied by a dose- 
dependent increase in cAMP release. The effects of PAMP were inhibited by 
HA1004, an inhibitor of protein kinase A. These results suggest that PAMP 
stimulates aldosterone secretion from the zona glomerulosa via cAMP. Ligand- 
binding studies were then used to demonstrate the presence of specific PAMP 
receptors. Two classes of receptor were shown in the rat zona glomerulosa (Kdi 
1.9 nmol/l, Bma, i 53 fmol/mg protein; Kd2 10 nmol/l, Bma, c2 225 fmol/mg 
protein). At the latter receptor PAMP was displaced by AM. None of the other 
competitors tested displaced PAMP. 
Using the H295R cell line, both PAMP and AM were shown to increase 
aldosterone secretion in a dose-dependent manner. In both cases a corresponding 
dose-dependent increase in cAMP was observed. Both PAMP and AM also 
effected a dose dependent increase in cortisol secretion. mRNA analysis showed 
that the gene encoding pre-pro-AM was expressed in these cells. 
Immunocytochemistry confirmed that these cells were producing both PAMP 
and AM. Immunocytochemistry and mRNA analysis also revealed that both of 
the candidate receptors for AM, L1 and CRLR, are expressed in this cell line. 
Taken together these findings demonstrate that both AM and PAMP are 
produced by adrenocortical cells and likely to have a role in regulating adrenal 
steroidogenesis. Furthermore, these studies suggest the presence of a specific 
PAMP receptor in the rat adrenal gland. 
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1 STRUCTURE OF THE ADRENAL GLAND (GROSS ANATOMY AND 
HtSTOLOGYI 
The adrenals are a paired gland lying anterior to the kidney in mammalian 
species. Its shape and proximity to the kidneys varies between species. In the 
human, the adrenal glands are in close proximity to the kidney and are triangular 
in shape, although the right and left adrenals are slightly different in shape to 
each other due to surrounding anatomical structures. In the rat however, the 
adrenal glands are more oval in shape and are not in such close proximity to the 
kidneys, being embedded in the perirenal fat. The adrenal glands are composed 
of two separate endocrine tissues which are both functionally and embryonically 
distinct. 
At the centre of the gland is the adrenal medulla which secretes 
catecholamines, derived from tyrosine. The medulla is formed in the neural crest 
during foetal development and migrates to the centre of the cortical tissue. 
Surrounding the adrenal medulla is the adrenal cortex. The adrenal cortex is 
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derived from the mesodermal lining of the coelom. During foetal development 
the adrenal cortex consists of a small outer definitive zone and a larger inner 
foetal zone, where the cells are arranged into cords which eventually circle round 
to enclose the medulla. At birth the adrenal gland is equal in size to the adult 
gland, however immediately after birth the gland decreases rapidly in size in part 
due to involution of the foetal zone. At this time there is also a maturation of the 
foetal zone into an inner fasciculata and reticularis. Six months after birth all the 
adult zones of the adrenal cortex are present. The adrenal gland grows slowly 
throughout childhood until puberty when a rapid increase in adrenal growth is 
observed and the gland reaches its adult size. There is no noted sexual 
dimorphism during adrenal development in the human (Neville and O'Hare 
1982). In the adult rat however, there is a well noted sexual dimorphism, with 
the female adrenal being approximately 50% larger in size than that of the male 
(Vinson et al. 1992). 
1.1 INNERVATION OF THE ADRENAL CORTEX 
Originally it was believed that there was no nerve supply to the adrenal cortex 
and that nerve bundles entering the gland passed directly to the medulla without 
branching (Elliott 1913). However, it is now known that the cortex, in particular 
the capsule and the zona glomerulosa are highly innervated. There are two 
different types of nerve which supply the adrenal cortex. The first has cell bodies 
outside the adrenal gland and enters the capsule along with blood vessels and 
functions independently of the splanchnic nerve. The second type is regulated by 
splanchnic nerve activity and has cell bodies located within the medulla (for 
review see Hinson 1990). Immunocytochemistry studies have since identified a 
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wide range of neuropeptides and neurotransmitters which are being supplied to 
the adrenal cortex. There is also evidence to suggest that these neurotransmitters 
and neuropeptides contribute to the regulation of steroid secretion from the 
adrenal cortex (for a review see Vinson et al. 1994). 
1.2 BLOOD SUPPLY TO THE ADRENAL CORTEX 
The adrenal gland is a highly vascular organ, with a vascular arrangement such 
that almost every cell of the adrenal cortex is adjacent to an endothelial cell 
(Vinson 1992). In the rat the adrenal gland receives approximately 0.14% of 
cardiac output despite making up only 0.02% of body weight (Sapirstein and 
Goldman 1959). Blood flow through the adrenal is actively regulated and is 
largely independent of systemic blood pressure. The adrenal gland receives its 
blood supply from multiple adrenal arteries which arise from the dorsal aorta. 
Blood is then supplied to the rest of the gland via a network of arterioles below 
the capsule which branch off to the rest of the gland (Vinson et al. 1992). 
Venous drainage occurs through a single central vein which discharges either 
into the renal vein (left adrenal) or directly into the vena cava (right adrenal; 
Vinson and Hinson 1992). Steroid secretion from the adrenal cortex is affected 
by rate of blood flow, a clear relationship being observed between the two 
(Hinson et al. 1986). 
1.3 ULTRASTRUCTURE OF THE ADRENAL CORTEX 
The first description of the adrenal cortex was made in 1866 by Arnold, who 
gave nomenclature to its three concentric zones, zona glomerulosa, zona 
fasciculata and zona reticularis (figure 1.1). Although Arnold's nomenclature for 
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these three zones was based purely on the histological organisation of cells 
within the tissue it is now known that this zonation extends to steroid hormone 
production, with each zone producing a distinct group of steroid hormones in 
response to different agonists. 
a. zona glomerulosa 
The adrenal gland is surrounded by a tough connective tissue capsule, directly 
beneath which is the zona glomerulosa. The cells of the glomerulosa are 
characteristically small and round in shape. In the rat, under normal conditions, 
the zona glomerulosa is typically 4-6 cells wide and makes up around 38% of the 
cortex. However, in the human, the glomerulosa makes up less of the cortex as 
the cells of the zona glomerulosa do not extend around the gland in a continuous 
shell but are isolated in clusters. Cells of the zona glomerulosa are also 
characterised by their mitochondria which are larger than those of other zones 
and have lamelliform cristae (Vinson et al. 1992). 
b. zona fasciculata 
In both the rat and human the zona fasciculata makes up the largest part of the 
adrenal cortex. The cells of this zone are much larger than those of the zona 
glomerulosa and are organised into centripetally orientated cords. Mitochondria 
are numerous, typically comprising 40% of cell volume. The cristae of these 
mitochondria are tubulovesicular in appearance. Smooth endoplasmic reticulum 
(sER) and lipid droplets are also abundant in the cells of the zona fasciculata 
(Vinson et al. 1992). 
c. zona reticularis 
The zona reticularis is the remaining zone of the adrenal cortex and lies between 
the zona fasciculata and the adrenal medulla. This zone is intermediate in size 
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compared to the other two zones, making up about one third of the cortex in 
humans. The cells of the zona reticularis are larger than those of the glomerulosa 
but smaller than those of the fasciculata. These cells are similar in shape to the 
cells of the zona fasciculata but are less well organised and contain fewer 
mitochondria, the cristae of which are also tubulovesicular in appearance. As in 
the other zones of the adrenal cortex sER and lipid droplets are abundant (Vinson 
et al. 1992). 
18 
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2 STEROID BIOSYNTHESIS IN THE ADRENAL CORTEX 
The adrenal gland synthesises the widest range of steroid compounds of all 
endocrine glands. These steroids are all derived from cholesterol, itself derived 
from a cyclopentanophenanthrene nucleus (Fraser 1992). Cholesterol (figure 1.2) 
consists of four rings, three six-carbon rings (denoted A, B and C) and one five- 
carbon ring (denoted D). These four rings are joined in a trans configuration to 
give a planar structure with an eight-carbon hydrophobic side chain. There is a 
hydroxyl group at C-3 and a double bond between C-5 and C-6. Different 
categories of steroid hormone are classified by the number, location and 
orientation of substituent groups, as well as by the length of the side chain. 
Substituent groups projecting below the molecule are designated a and those 
projecting above the paper are designated P. Side chain substituents are 
designated by the R (rectus) and S (sinster) system. Although all steroids are 
derived from the same parent structure relatively small changes in this structure 
can have a great effect on biological activity (Fraser 1992). 
The adrenal cortex can synthesise progesterone (C21), adrenal androgens 
(C19), adrenal oestrogens (C18) and corticosteroids (C21), all of which are derived 
from cholesterol. Glucocorticoids and mineralocorticoids comprise the 
corticosteroids which are structurally defined by: 
1) a double bond at C-4 and an oxo group at C-3. 
2) a two carbon side chain at C-17. 
3) a hydroxyl group at C-21 and an oxo group at C-20. 
4) presence/ absence of a hydroxyl group at C-17. 
20 
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OH 6 
FIGURE 1.2: Structure of cholesterol. 
5) presence/absence of a hydroxy/ketone group at C-11. 
The corticosteroids can be loosely grouped as either 17-hydroxylated or 
non-17-hydroxylated. While it is generally held that the former group tends to 
exhibit more potent glucocorticoid activity than mineralocorticoid activity, the 
reverse being true for the latter group, there is some overlap (Gower 1984). 
2.1 CHOLESTEROL 
There are two available sources of cholesterol for steroid biosynthesis in the 
adrenal cortex. It can be synthesised de novo from acetate (Goad 1984). The rate 
limiting step for which is conversion of 3-hydroxy-3-methylglutaryl-CoA (HMG- 
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CoA) to (3R)-mevalonic acid by the microsomal enzyme, HMG-CoA reductase. 
Cholesterol may also be sequestered from circulating plasma lipoproteins, from 
low-density lipoproteins (LDL) in human and bovine (Kovanen et al. 1979; Carr 
et al. 1980) and from high-density lipoproteins (HDL) in rat (Gwynne and Hess 
1980; Gwynne et al. 1976). Uptake of cholesterol by cells is facilitated by 
receptor mediated endocytosis (Toth 1992; Brown et al. 1979). Cholesterol is 
stored in esterified from in cytoplasmic lipid droplets of the adrenal cortex, 
requiring cholesterol ester hydrolayse (CEH) for its release (Boyd et al. 1983). 
2.2 STEROIDOGENIC ENZYMES 
Steroid production from cholesterol involves two types of reaction, hydroxylation 
and oxidation-reduction. The hydroxylation steps are carried out by a series of 
mixed function oxidases (hydroxylases) and the oxidation-reduction steps are 
carried out by a range of hydroxysteroid ehydrogenases. 
2.2.1 CYTOCHROME P450 
The hydroxylases required for steroid biosynthesis are a family of haem- 
containing monooxygenases termed cytochrome P450 (P450). Their name is 
derived from the fact that they exhibit a characteristic shift in the Soret 
absorbency from 420nm to 450nm upon reduction with carbon monoxide. They 
catalyse the oxidation of the steroid molecule with one molecule of oxygen 
(Fraser 1992): 
STEROID-H + NADPH + H* + 02 -*STEROID-OH + NADP` + H2O 
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These enzymes require NAD(P)H as a co-factor as a source of reducing power. 
In mitochondria adrenodoxin, a non-haem iron-sulphur protein is also required as 
a redox component, involving the FAD-containing flavoprotein NADPH- 
adrenodoxin reductase to facilitate the transfer of electrons (figure 1.3). The 
mechanism of action of steroid hydroxylation by P450 is illustrated in figure 1.4. 
A single iron protoporphrin prosthetic group is located at the active site of the 
P450 enzymes, at which dioxygen is bound, reduced and activated. 
The NADPH required to support steroidogenesis is generated in the 
cytosol by the glucose-6-phosphate dehydrogenase reaction. The mitochondria 
are supplied with reducing equivalents via a `malate shuttle'. Malate can be 
converted into pyruvate, generating NADPH, via a reversible reaction which 
favours pyruvate synthesis in the mitochondria and malate synthesis in the 
cytosol. Additionally, in rat mitochondria NADPH may also be generated from 
the conversion of isocitrate to a-ketoglutarate by isocitrate dehydrogenase. 
There are five different P450 enzymes involved in steroidogenesis within 
the adrenal gland. The first of these, P450s,,, is found in the mitochondria. This 
enzyme catalyses the cleavage of the side chain on the cholesterol molecule to 
form pregnenolone. P450. is coded for by the CYP11A gene. P45017 and 
P45021, coded for by CYP17 and CYP21 respectively, are located in the 
endoplasmic reticulum. P45017 is essential in the production of cortisol and 
adrenal androgens. P45017 is expressed in the zona fasciculata and the zona 
reticularis of the adrenal cortex. This enzyme is not present in the rat adrenal 
cortex, hence rats are unable to synthesise cortisol or adrenal androgens. P45021 
is essential in both mineralocorticoid and glucocorticoid production. 
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ENDOPLASMIC RETICULUM 
NADPH -+ P450 reductase -> P45017, P45021 
MITOCHONDRIA 
NADPH -+ Adrenodoxin reductase -+ Adrenodoxin -ý P450.,, P450, I p 
FIGURE 1.3: The transfer of reducing equivalents from NADPH to steroid 
hydroxylases in the adrenal cortex (adapted from Simpson and 
Waterman 1992). 
There has been some controversy surrounding the final stages in the 
production of aldosterone and cortisol, namely the 11 ß-hydroxylase and the 18- 
hydroxylase activity. Until recently it was thought that both of these activities 
were present on the same enzyme named, P450111Y18. However, it is now known 
that there are two separate enzymes, 11 ß-hydroxylase and aldosterone synthase, 
coded for by two separate genes, CYP11B1 and CYP11B2 respectively, which are 
located on different chromosomes (Muller 1993). CYPIIB2 is expressed solely 
in the zona glomerulosa and aldosterone synthase catalyses the formation of 
aldosterone, however 11 ß-hydroxylase does not (Hanukoglu 1992). The 
expression of CYPIIB2 is regulated by dietary sodium restriction, potassium 
loading and the renin-angiotensin system (Imai et aL 1992; LeHoux and 
Tremblay 1992). CYPIIBI is mainly expressed in the zona fasciculata and its 
expression is regulated by ACTH. 
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FIGURE 1.4: Events probably catalysed by cytochrome P450 during steroid 
hydroxylation. i) Steroid interacts with P450 to give the ferric 
complex; ii) one electron reduction; iii) formation of the P450- 
steroid-02 complex; iv) one electron reduction; v) addition of 
2H' and elimination of H2O to produce an activated atomic 
oxygen species. [] = proposed intermediate. Adapted from 
Vinson et al. (1992). 
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2.2 STEROID DEHYDROGENASES 
a. 30-hydroxysteroid ehydrogenase/ isomerase (30-HSD) 
Two types of reaction are catalysed by this microsomal enzyme, 
conversion of 3(3-hydroxy-5-ene steroids to a 3-keto-4-ene configuration and 5- 
ene-4-ene isomerisation (Hanukoglu 1992). Both pregnenolone and DHEA can 
act as a substrate for 3ß-HSD, for which NADP+ is the preferred co-factor, 
yielding progesterone and androstenedione respectively. The isomerase reaction 
appears to require no co-factor. 
b. 11 ß-hydroxysteroid dehydrogenase (11 ß-HSD) 
This enzyme catalyses the interconversion of physiologically active 
glucocorticoids (cortisol in human and corticosterone in rat) to their 
physiologically inactive 11-keto forms (cortisone in human and 11- 
dehydrocorticosterone in rat) by reduction and dehydrogenation at C-11. There 
are two isoforms of the enzyme, type-I catalyses the reductase activity and 
utilised NADPH as a co-factor while type-II catalyses the dehydrogenase activity 
and uses NAD+ as a co factor. They are predominantly located in the liver and 
kidney, respectively, although they are weakly present, by comparison, in the 
adrenal gland of several species. Both isoforms regulate circulating levels of 
corticosteroids. This enzyme confers tissue specificity to mineralocorticoid 
receptors, for which physiologically active glucocorticoids are just as effective 
ligands as aldosterone, by converting cortisol and corticosterone to cortisone and 
11-deoxycorticosterone, respectively. Deficiency of 11 ß-HSD leads to the 
condition of apparent mineralocorticoid excess (AME: Miller 1988). This 
enzyme forms a unique mechanism for conferring enzyme mediated, not receptor 
0 
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mediated, tissue specificity (White et al. 1992; Funder et al. 1988; Stewart et al. 
1987). 
c. 170-hydroxysteroid ehydrogenase (170-HSD) 
This microsomal enzyme is present in the adrenal but is less active here 
than in the gonads (Vinson et al. 1992). 170-HSD catalyses the reversible 
formation of 17-keto and 17-hydroxy groups in androgens and oestrogens. 170- 
HSD requires NADPH as a co-factor. 
2.3 BIOSYNTHESIS OF ADRENAL STEROIDS 
Free cholesterol, released from lipid droplets by cholesterol ester hydrolase, is 
transported in two stages to the inner mitochondrial membrane. Transport to the 
outer mitochondrial membrane requires intact cytoskeleton (reviewed in Fraser 
1992). Cholesterol must then be transported to the inner mitochondrial 
membrane as P450scc is located on the matrix side of the inner mitochondrial 
membrane (Farkash et al. 1986). Previously it was thought that the rate limiting 
step in steroidogenesis was conversion of pregnenolone from cholesterol. 
However, it is now known that this is not the case and that the rate limiting step 
of steroidogenesis is the transport of cholesterol from the outer to the inner 
mitochondrial membrane. This transport is most likely facilitated by steroid 
acute regulatory protein (StAR). However, the exact mechanism by which StAR 
transports cholesterol to the inner mitochondrial membrane is not completely 
understood at this time (for review see Stocco 1999). At the inner mitochondrial 
membrane cholesterol comes into contact with cytochrome P450, cc, which 
catalyses hydroxylation at two adjacent carbon atoms, 20a and 22R. P4508cc also 
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catalyses the cleavage of the side chain to yield pregnenolone, which must then 
be translocated to the endoplasmic reticulum for further processing. 
There are two routes by which cortisol may be formed from 
pregnenolone. By the first of these routes pregnenolone is converted to 
progesterone by the oxidation of the 30-hydroxyl group. Progesterone can then 
act as a substrate for P45017 and the hydroxylation at C17 results in the formation 
of 17a-hydroxyprogesterone. The second route by which pregnenolone is 
converted to 17a-hydroxyprogesterone, pregnenolone first acts as a substrate for 
P45017 forming 17a-hydroxypregnenolone which is in turn converted to 17a- 
hydroxyprogesterone by 30-HSD. 11-Deoxycortisol is formed from 17a- 
hydroxyprogesterone by P45021. It is then transported back to the mitochondria 
where it is acted upon by P45011 to form cortisol, the major glucocorticoid in the 
human. In the rat, which possesses negligible P45017 activity, the major 
glucocorticoid is corticosterone which is produced from progesterone, first by 
the action of P45021 to form deoxycorticosterone which is then converted to 
corticosterone by P45011. Aldosterone, the major mineralocorticoid in both 
human and rat, is then produced by the metabolism of corticosterone by P45018 to 
yield first 18-hydroxycorticosterone then aldosterone (Fraser 1992; Vinson et al. 
1992). 
Production of adrenal androgens takes place entirely in the endoplasmic 
reticulum. 17a-hydroxypregnenolone and 17a-hydroxyprogesterone can be 
further acted on by P45017 to form DHEA and androstenedione respectively. 
DHEA can also be converted to androstenedione by 30-HSD. 170-HSD can then 
convert androstenedione to testosterone. In mammals adrenal androgen synthesis 
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takes place in the zona reticularis, however in the rat, only low levels of androgen 
are produced because of the low levels of CYP17 expression (Vinson et al. 
1992). 
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FIGURE 1.5: Pathway illustrating the steps in steroid hormone biosynthesis. 
Arrows mark the conversion of substrate to product by the enzyme 
named in the box. Enzymes enclosed by solid boxes are present 
in the mitochondria while those enclosed by boxes with broken 
lines are present in the endoplasmic reticulum. Adapted from 
Hanukoglu (1992). 
30 
Chapter 1: Introduction and Literature Review 
3 REGULATION OF STEROID SECRETION 
3.1 PHYSIOLOGICAL REGULATION OF ALDOSTERONE SECRETION 
Aldosterone is the predominant mineralocorticoid secreted by the zona 
glomerulosa of the adrenal cortex. The function of aldosterone is to promote 
reabsorption of sodium ions (Na) in the kidney by exchange with potassium ions 
(K). Unlike steroid secretion from the zona fasciculata, which falls almost 
entirely under the regulation of the pituitary hormone ACTH, secretion of 
aldosterone from the zona glomerulosa is regulated by altered electrolyte balance, 
involving a number of factors in a series of complex interactions. 
3.1.1 THE RENIN-ANGIOTENSIN SYSTEM 
One of the most potent stimulants to aldosterone secretion in vivo is angiotensin 
II (All), a component of the renin angiotensin system. In the event of reduced 
sodium balance the renin-angiotensin system is activated and an increase in 
plasma renin is observed. Renin is a proteolytic enzyme secreted by the 
juxtaglomerular cells of the afferent arteriole of the kidney in response to reduced 
plasma sodium concentration. Although the kidney is the major source of renin it 
has also been located in a variety of other tissues including the adrenal gland 
(Phillips et al. 1993; Mulrow 1992). Renin production can also be stimulated by 
catecholamines and glucagon, although the physiological relevance of these are 
unclear (Valloton 1987). This enzyme forms angiotensin I, a relatively inactive 
decapeptide, by cleaving angiotensinogen a protein secreted from the liver. 
Angiotensin I has a relatively short half life in the body and is rapidly cleaved by 
angiotensin converting enzyme (ACE) to form angiotensin II (an octapeptide). 
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ACE is predominantly found in the vascular epithelium of the lung, but has also 
been found in liver, pancreas, spleen and the adrenal cortex. The increase in 
aldosterone secretion observed in the event of reduced sodium can be blocked by 
the administration of an ACE inhibitor such as captopril (Aguilera et al. 1978). 
All is rapidly broken down in both circulation and target tissues by 
aminopeptidases. One of these aminopeptidases, aminopeptidase A, cleaves the 
N-terminal aspartate from All to form angiotensin III (AIII). While All is the 
most potent physiological stimulant of aldosterone secretion, AIII has also been 
shown to have an aldosterone stimulating effect in several species including rat 
and human (Aguilera et al. 1979; Kono et al. 1975). 
Specific All binding sites have been identified in the adrenal cortex. 
They are located predominantly in the zona glomerulosa although they have also 
been identified in the inner zones of the adrenal cortex, where they are far less 
numerous (Douglas et al. 1984; Douglas et al. 1978). The inner zones of the 
adrenal cortex have been shown to secrete steroids in response to All although 
they are much less responsive to All than the zona glomerulosa and there is a 
great deal of species variation. 
3.1.2 THE ROLE OF POTASSIUM 
Potassium ions (K), which are excreted by the kidney in response to aldosterone, 
are also involved in the regulation of aldosterone secretion from the adrenal 
cortex. Potassium was first shown to have a stimulatory effect on aldosterone 
secretion in rat adrenal glands (Giroud et al. 1956). Studies in normal man 
showed that an increase in serum K' resulted in a significant increase in plasma 
aldosterone without altering plasma corticosterone or cortisol (Dluhy et al. 1972). 
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Studies using the rat isolated perfused adrenal gland in situ also reported that 
stimulation of aldosterone in response to IC was not paralleled by an increase in 
corticosterone secretion (Hinson et al. 1985). In addition to these direct effects 
of IC on aldosterone secretion, K+ also increases sensitivity of the adrenal gland 
to angiotensin II (Douglas and Catt 1976; Douglas 1980). 
3.1.3 ACTH AND PITUITARY PEPTIDES 
The pituitary gland also has an important role in regulating zona glomerulosa 
function (Muller 1987). Experimental data have shown that the pituitary gland is 
necessary for regulation of electrolyte balance as the aldosterone response to 
sodium depletion is impaired in hypophysectomised rats and in humans with 
impaired pituitary function (Palmore et al. 1970). ACTH, the predominant 
regulator of steroid secretion from the zona fasciculata, is also involved in 
regulation of aldosterone secretion from the zona glomerulosa both in vivo and in 
vitro. Chronic administration of ACTH or excess secretion of endogenous 
ACTH result in decreased aldosterone secretion by transforming zona 
glomerulosa cells into zona fasciculata type cells (Vazir et al. 1982; Abayasekara 
et al. 1989). However, short term administration of ACTH gives rise to an 
increase in aldosterone secretion in several species including rat and human 
(Giroud et at 1956; Dyrenfurth et al. 1960). In fact, in vitro ACTH is the most 
potent stimulator of aldosterone secretion (Haning et al. 1970). However, 
ACTH does not restore aldosterone secretion in hypophysectomized rats 
(Shenker et al. 1985). 
Other pituitary peptides which have an effect on aldosterone secretion are 
the melanocyte-stimulating hormones (MSH), which are also derived from pro- 
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opiomelanocortin (POMC). a-MSH has been shown to stimulate aldosterone 
secretion both in vivo and in vitro (Henville et al. 1989; Vinson et al. 1983). ß- 
MSH has also been shown to stimulate aldosterone secretion (Matsuoka et al. 
1981). 
3.1.4 PARACRINE/ AUTOCRINE REGULATION 
The method used to study adrenal function can have a variety of responses, 
particularly in the case of aldosterone secretion (Vinson et al. 1985). Classical 
tissue preparation methods, such as collagenase digestion, while giving a cell 
suspension with low basal steroid secretion rates destroys gland vasculature and 
innervation. The effects of neuropeptides, if any, in the adrenal gland therefore 
remained unclear. The method of in situ perfusion of the rat adrenal gland 
(Hinson et al. 1985) allowed steroid secretion to be observed with both 
vasculature and innervation intact. 
Prior to this many neuropeptides had been identified in neurones 
supplying the adrenal capsule and the zona glomerulosa. Vasoactive intestinal 
peptide (VIP) was the first of these to be located in neurones of the rat adrenal 
gland (Hökfelt et al. 1981; Holzwarth 1984). VIP was shown to stimulate 
aldosterone secretion in vivo, but only in the presence of ACTH (Enyedi et al. 
1983). VIP has also however, been reported to stimulate cortisol secretion in the 
H295R cell line (Cobb et al. 1997). When administered on its own there was no 
effect on aldosterone secretion (Nussdorfer et al. 1987). Neuropeptide Y (NPY) 
which is found in the adrenal medulla has also been located in intra-adrenal 
nerves of the rat (Kuramoto 1986). Specific receptors for NPY have been 
detected in bovine zona glomerulosa but not other areas of the adrenal gland 
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(Torda et a!. 1988). NPY has been shown to stimulate aldosterone secretion 
from intact rat adrenal capsular tissue and also in the intact perfused rat adrenal 
gland (Renshaw et al. 2000; Hinson et a!. 1994). In the rat NPY is co-localised 
with VIP (Maubert et a!. 1990). Calcitonin gene-related peptide (CGRP) has also 
been identified in nerves supplying the adrenal gland (Kuramoto et at. 1985). 
CGRP receptors have also been located within the adrenal gland (Goltzman and 
Mitchell 1985). Studies in rat and rabbit have shown that CGRP inhibits 
aldosterone secretion (Mazzocchi et a!. 1992; Murakami et a!. 1989). However, 
in the perfused rat adrenal an increase in perfusion flow rate, aldosterone and 
corticosterone secretion was observed in the presence of CGRP (Hinson and 
Vinson 1990). 
Endothelin-1 (ET-1) is a peptide secreted from the vascular endothelium 
and has vasoconstrictor properties (Yanagisawa et a!. 1988). ET-1 has been 
shown to stimulate aldosterone secretion in the rat both in vivo and in vitro 
(Mazzocchi et a!. 1990). Similar effects of ET-1 have also been reported in calf, 
rabbit and human zona glomerulosa cells (Cozza et a!. 1989; Morishita et a!. 
1989; Hinson et al. 1991). 
More recently immunocytochemistry studies have revealed the presence 
of ET-1 in zona glomerulosa cells, suggesting an autocrine as well as paracrine 
role for ET-1 in zona glomerulosa function (Naruse et a!. 1994). 
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3.1.5 INHIBITORS OF ALDOSTERONE SECRETION 
There are three main inhibitors of aldosterone secretion, atrial natriuretic peptide, 
dopamine and somatostatin. ANP inhibits aldosterone secretion both in vivo and 
in vitro (Chartier et al. 1984) and it is likely that ANP has a physiologic role in 
aldosterone secretion as it inhibits both basal and stimulated aldosterone 
secretion (Kudo et at 1984). The mechanism by which ANP inhibits aldosterone 
secretion is at this time unclear. However, ANP is known to increase cGMP and 
inhibit adenylate cyclase activity and its inhibitory effect in the adrenal gland may 
be mediated via one of these second messengers. ANP does not bind to All or 
ACTH receptors (DeLean et at 1984) and specific ANP receptors have been 
located in the adrenal gland (Choi et at 1986; Lynch et at 1986). ANP has also 
been shown to inhibit renin (Kurtz eta!. 1986). 
Dopamine inhibits both All-mediated (McKenna et at 1979) and 
potassium-mediated (Fitzpatrick and McKenna 1989) aldosterone secretion in 
vitro, although only at high concentrations. Although specific receptors for 
dopamine have been located in the zona glomerulosa (Dunn et at 1981), it is at 
this time unclear the mechanism by which dopamine inhibits aldosterone 
secretion. 
Somatostatin is secreted by the hypothalamus and acts on the pituitary 
gland to inhibit the production of growth hormone. Somatostatin receptors have 
been detected in rat adrenal zona glomerulosa (Aguilera et at 1982). When 
administered in vivo somatostatin inhibits aldosterone secretion. Somatostatin 
has also been shown to inhibit All-stimulated aldosterone secretion (Aguilera et 











In contrast with the multifactorial regulation of aldosterone biosynthesis secretion 
of glucocorticoids by the zona fasciculata falls almost entirely under the 
regulation of the hypothalamus-pituitary-adrenal axis. Within 2 hours of 
hypophysectomy circulating levels of glucocorticoids have decreased 
significantly. This drop, however, can be avoided by administration of a single 
dose of ACTH (Li 1962). 
ACTH is secreted by the corticotroph cells of the anterior pituitary gland 
and is a cleavage product of a larger precursor molecule, pro-opiomelanocortin 
(POMC), which also gives rise to melanocortins, ß-lipotrophin and endorphin. 
ACTH is a 39 amino acid peptide hormone. However, full biological activity is 
conferred by residues 1-24. This region of the peptide is highly conserved among 
species, in particular the lys-lys-arg-arg sequence at residues 15-18, which are 
thought to have a role in receptor binding (Hoffman et al. 1970) and residues 4- 
10 which are thought to be involved in receptor activation (Schwyser et al. 1971). 
Residues 25-39 are less well conserved between the species and are thought to 
act in a protective manner to prevent proteolytic breakdown (Baumann and 
Felber 1976), although evidence for this is not conclusive. ACTH, like many 
hormones, exhibits a distinct diurnal rhythm with levels in man peak in the 
morning, 6-9 am and decreases throughout the day to reach a low in the evening. 
The converse of this is true in the rat, with peak ACTH secretion being observed 
in the evening (Vinson et al. 1992, book review). 
Secretion of ACTH also falls under the control of the HPA axis, being 
regulated by corticotrophin releasing hormone (CRH 41), arginine vasopressin 
and adrenaline (Jones and Giliham 1988). CRH 41 is a peptide hormone secreted 
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by the hypothalamus in response to stress, both emotional and physical, and 
regulated by negative feedback by glucocorticoids from the adrenal gland. 
Negative feedback by glucocorticoids also acts on the pituitary to inhibit ACTH 
secretion. 
As well as increasing glucocorticoid secretion directly ACTH also acts as 
a vasodilator (for review see, Vinson and Hinson 1992) increasing the rate of 
blood flow through the adrenal gland, which also increases steroidogenesis 
(Hinson et al. 1986). 
3.3 PHYSIOLOGICAL REGULATION OF ADRENAL ANDROGEN 
SECRETION 
Under basal conditions, adrenal androgens are preferentially secreted by the zona 
reticularis of the adrenal cortex (Davidson et al. 1983; O'Hare et al. 1980). In 
postmenopausal women, adrenal androgens are the major source of androgens. 
However, in men the amount of androgens secreted by the adrenal are relatively 
small compared to secretion by the testes. Several C-19 are secreted by the zona 
reticularis, including androstenedione, 11 ß-hydroxy-androstenedione, 
testosterone, dehydroepiandrosterone (DHEA) and dehydroepiandrosterone- 
sulphate (RHEAS), of these the most abundant is DHEAS. Adrenal androgen 
secretion is also increased in the presence of ACTH in vivo (Irvine et al. 1974; 
Rosenfeld et al. 1971) although cells of the zona reticularis do not respond well 
to ACTH in vitro (Davidson et al. 1983; Bell et al. 1979). Adrenal androgen 
secretion however, does not fall entirely under the regulation of ACTH as under 
certain conditions, for example puberty, adrenal androgen secretion is dissociated 
from ACTH and cortisol secretion (for review see Parker and Odell 1980). This 
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has suggested the existence of a specific factor which stimulates adrenal 
androgen secretion (Odell and Parker 1980). Although several factors have been 
suggested which may increase adrenal androgen secretion to date none of them 
have been confirmed and it has also been postulated that control of steroid 
secretion by the zona reticularis may in part be regulated by the abundance of 
other steroid hormones produced within the adrenal cortex (Anderson 1980). 
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4 RECEPTORS AND SECOND MESSENGERS IN THE ADRENAL 
CORTEX 
4.1 ACTH RECEPTORS 
The ACTH receptor is a 7-transmembrane domain receptor and is a member of 
the melanocortin receptor family (Mountjoy et al. 1992). The ACTH receptor is 
coupled to a guanine nucleotide-binding protein (G-protein) which activates 
adenylate cyclase and thus generates cAMP. ACTH binds to its receptor causing 
a conformational change which allows a non-covalent interaction between the 
ACTH receptor and a stimulatory G-protein (Gs) to take place. Gs then releases 
guanosine diphosphate (GDP) and binds magnesium complexed guanosine 
triphosphate (GTP), which exposed a binding site for adenylate cyclase. Binding 
to the Gs activates adenylate cyclase which then converts adenosine triphosphate 
(ATP) to cAMP (Ross and Gillman 1980). cAMP can then activate cAMP - 
dependent protein kinase (PKA). Activation of PKA releases a catalytic subunit 
which can then phosphorylate a number of target proteins. One such target is the 
cAMP response element binding protein (CREB) which binds to DNA sequence 
in the promoter region of genes known as cAMP response element (CRE). 
Phosphorylation by PKA on ser133 of CREB enhances transcription by promoting 
interaction with RNA polymerase 11 (for review see Montminy 1997). Of the 
genes which code for enzymes involved in steroidogenic enzymes CRE is found 
only in the promoter regions of two of them, CYPIIBI and CYP11B2, which 
code for 11 ß-hydroxylase and aldosterone synthase respectively (Morohashi et al. 
1993). However, other genes encoding steroidogenic enzymes, CYP1IA, 
CYP17 and CYP21, are regulated by ACTH and cAMP to give an increase in 
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steroid synthesis. This would therefore suggest that other regulatory processes or 
more discrete CRE's are involved in regulation of these genes by ACTH and 
cAMP (Morohashi et al. 1993). 
ACTH was first shown to activate adenylate cyclase activity in the 
adrenal by Haynes and co-workers (Haynes and Berther 1957) with the 
observation of an increase in cAMP in response to ACTH which mimicked the 
increase observed in ACTH-induced steroidogenesis. These findings were later 
confirmed (Grahame-Smith et al. 1967; Ney et al. 1969) with the reported 
observations of a dose-dependent increase in cAMP formation which preceded 
the onset of increased steroidogenesis. It was not until 1992 that the ACTH 
receptor was cloned (Mountjoy et al. 1992). Sequence analysis revealed that the 
ACTH receptor was a small G-protein coupled receptor of only 297 amino acids 
in length. 
4.2 ANGIOTENSIN II RECEPTORS 
The presence of All receptors in the adrenal gland was first demonstrated by Lin 
and Goodfriend (1970). Autoradiography studies revealed specific All binding 
sites in the zona glomerulosa of rat adrenal cortex. In the adrenal gland the 
majority of All receptors are located in the zona glomerulosa and the medulla, 
with very few receptors being found in the zonae fasciculata or reticularis 
(Douglas et al. 1978; Maurer and Reubi 1986). 
There are currently three characterised subtypes of the angiotensin 
receptor, ATE, AT2 and AT3, although the AT3 receptor is less well characterised 
than the others (Bottari et at. 1993). The AT1 receptor is thought to be 
responsible for the main biological effects of All, including aldosterone secretion 
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from the zona glomerulosa. The effects of antagonists of the AT1 receptor have 
shown that this receptor is responsible for aldosterone production, All-stimulated 
phosphoinositide turnover and All-induced inhibition of ACTH stimulated 
adenylate cyclase activity (Aguilera 1992). 
Binding of All to its receptor activates phospholipase C (PLC), which in 
turn hydrolyses phosphatidylinositol to generate inositol-1,4,5-trisphosphate (IP3) 
and diacylglycerol (DAG), both of which signal in different ways. IP3 liberates 
Ca2+ from intracellular stores by binding to IP3-gated Ca2+ channels in the 
endoplasmic reticulum membrane followed by influx of extracellular Ca2+, 
leading to a sustained elevation of intracellular Ca2+ (Kojima et al. 1985). DAG 
activates a Ca2+-dependent, phospholipid-dependent protein kinase (PKC), which 
catalyses the phosphorylation of serine and threonine residues of various cellular 
proteins (Kaibuchi et al. 1981). PKC can stimulate gene transcription by 
activation of a mitogen activated protein kinase (MAPK) pathway which results 
in the phosphorylation and activation of a DNA-bound gene regulatory protein 
(Elk-1: Nishizuka 1992). Alternatively PKC can stimulate gene transcription by 
phosphorylation of an inhibitor protein (1KB) which releases a gene regulatory 
protein (NFKB) which can then activate the transcription of specific genes (Liou 
et al. 1993). Experimentally, PKC is commonly activated by the phorbol ester 
12-0-tetradecanoyl phorbol-13-acetate (TPA). DAG can be further cleaved to 
release arachidonic acid. 
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5 PRE-PRO-ADRENOMEDULLIN DERIVED PEPTIDES 
Adrenomedullin (AM) is a peptide which was first identified by Kitamura et al. 
(1993). It was extracted from a pheochromocytoma and was identified by its 
ability to elevate cAMP levels in rat platelets. The same group then cloned the 
human gene encoding adrenomedullin (Kitamura et al. 1993) and later the gene 
encoding rat adrenomedullin (Sakata et al. 1993). Since then the gene encoding 
adrenomedullin has been cloned in several species including canine, bovine and 
porcine (Kitamura et al. 1994; Barker et al. 1998; Ono et al. 1998). 
Adrenomedullin shows some homology with calcitonin gene related peptide 
(CGRP) and has been grouped as part of the CGRP peptide superfamily, which 
also include amylin and calcitonin. 
Analysis of the cDNA sequence of the cloned adrenomedullin gene 
revealed a potential second novel peptide in the N-terminal region of the peptide, 
which was named proadrenomedullin N-terminal 20 peptide (PAMP; Kitamura et 
al. 1993). This same group then developed a radioimmunoassay for PAMP and 
revealed the presence of PAMP in plasma and various tissues (Washimine et al. 
1994). 
Human adrenomedullin is a 52 amino acid peptide which is amidated at 
the carboxy terminal tyrosine residue and has a single disulphide bridge between 
residues cys16 and cys21 (figure 1.6a), both of these features are thought to be 
essential for biological activity (Kitamura et al. 1993). Rat adrenomedullin has 
only 50 amino acids and, in addition to these two deletions, it also differs from 
the human peptide by 6 substitutions (Sakata et al. 1993). Both human and rat 
PAMP are 20 amino acids in length (figure 1.6b) and differ from each other in 
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FIGURE 1.6: Amino acid sequence of a) adrenomedullin and b) PAMP. 
Adapted from Samson (1998). 
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only two positions (Kitamura et al. 1993; Sakata et al. 1993). 
Adrenomedullin is cleaved from a larger precursor molecule, termed pre- 
proAM, which is 185 amino acids in length in both human and rat (Kitamura et 
al. 1993; Sakata et al. 1993) and is encoded by the adrenomedullin gene. This 
gene is located on chromosome 11 and is composed of 4 exons and 3 introns 
(Ishimitsu et al. 1994). Adrenomedullin is encoded for entirely within exon 4 of 
the pre-proAM gene and PAMP is coded for on exons 2 and 3 (figure 1.7). 
There are several regulatory elements in the 5' flanking region of the gene 
including CAAT, TATA and GC boxes, all of which are essential for basal gene 
expression. There is also a cAMP-regulated enhancer element. Several studies 
have shown increases in cAMP release in response to adrenomedullin (Ishizaka 
et al. 1994; Kapas et al. 1998), and a recent study has shown a decrease in 
cellular adrenomedullin in response to cAMP (Kobayashi et al. 1999). A binding 
site for activator protein-1 (AP-1) and several binding sites for AP-2 have also 
been identified in the 5' flanking region of the adrenomedullin gene which may 
be involved in transcriptional activation by phorbol esters, and hence be involved 
in cell proliferation, and PKC respectively (Ishimitsu et al. 1994). There is also a 
binding site for NFKJ3 in the 5' flanking region of the adrenomedullin gene which 
is also involved in transcriptional activation by PKC (Ishimitsu et al. 1994). 
The first processing of the adrenomedullin gene towards the mature 
peptides is cleavage of a 21 amino acid signal peptide, from the initiating Met 
codon to Thr21-Alan, to generate a 164 amino acid peptide termed 
proadrenomedullin (figure 1.7ý Ishimitsu et al. 1994). Adrenomedullin is excised 
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from proAM by cleavage at two pairs of basic amino acids, Lys93-Arg94 and 
Arg 148-Arg 149. PAMP is release from proadrenomedullin by cleavage at another 
pair of basic residues, Lys43-Arg44 (Ishimitsu et al. 1994). Cleavage at these sites 
leaves both peptides with a carboxy terminal Gly residue, Tyr146-Gly147 in the 
case of adrenomedullin and Arg41-G1y42 in the case of PAMP. These Gly 
residues contribute to an amide structure at the carboxy terminus of both 
adrenomedullin and PAMP (Kitamura et al. 1993). Recently however, it has 
been suggested that this intermediate glycine-extended form of adrenomedullin is 
the main form in circulation (Kitamura et al. 1998). 
Adrenomedullin is expressed within a variety of tissues (reviewed in 
Samson 1998) although it is not constitutively expressed, not being located in the 
rat zona fasciculata (Kapas et al. 1998) among other tissues (for review see 
Hinson et al. 2000). Adrenomedullin has also been shown to be expressed in 
endothelial cells and therefore some of its expression can be accounted for by 
vascular endothelium (Sugo et al. 1994). The vascular endothelium does not 
entirely account for the presence of adrenomedullin in tissue as studies have 
shown adrenomedullin expression in cells and in cell lines (Miller et al. 1999). 
In addition to being expressed in a variety of tissues adrenomedullin is also found 
in plasma. Circulating levels of adrenomedullin in human are typically 1-10 pM 
(Lewis et al. 1998; Sato et al. 1995; for review see Hinson et al. 2000). 
Similarly, in the rat circulating levels of adrenomedullin are in the low pM range, 
3.6pM (Sakata et al. 1994). However, no tissue has as yet been identified as the 
major source of circulating adrenomedullin (Nishikimi et al., 1994). Studies in 
the pancreas have provided evidence that adrenomedullin is stored in secretory 
granules (Martinez et al. 1996). However to date, no other tissues have been 
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investigated at the electron microscope level and it is unclear as to whether these 
storage granules are a feature common to adrenomedullin expressing cells. There 
is however no evidence for storage of adrenomedullin by cells, when the 
adrenomedullin content of cultured cells is compared with the concentration of 
adrenomedullin secreted into the culture medium (Takahashi et al. 1998). It is 
thought that adrenomedullin may be constitutively secreted (Isumi et al. 1998). 
5.1 REGULATION OF PRODUCTION 
While complex transcriptional regulation is involved in the production of 
adrenomedullin the exact mechanism by which transcription of the 
adrenomedullin gene is regulated has so far not been clearly defined (Hattori et 
al. 1999). Studies in human endothelial cells have shown the NF-IL6 and the 
AP-2 sites in the promoter region of the pre-proadrenomedullin gene to be 
functional elements in the transcriptional regulation of this gene (Ishimitsu et al. 
1998). Adrenomedullin gene transcription has been shown to be stimulated by 
lipopolysaccharide (LPS), interleukin-1 (IL-1) and tumour necrosis factor alpha 
(TNF-a) in rat vascular smooth muscle cells (VSMC; Sugo et al. 1995). 
However, in glioma cells TNF-a inhibited adrenomedullin gene transcription 
(Takahashi et al. 1997). This would suggest that the regulation of 
adrenomedullin gene transcription may not be the same in all tissues, with 
different factors promoting or blocking transcription in different cell types. 
Production of adrenomedullin in endothelial cells is also stimulated by 
cytokines, growth factors and mineralo- and glucocorticoids and was inhibited by 
endothelin-1, CGRP, and transforming growth factor beta (TGFI; Isumi et al. 
1998). This study also showed that forskolin had no effect on adrenomedullin 
4R 
Chapter 1: Introduction and Literature Review 
production although other studies have reported that cAMP decreased 
adrenomedullin production (Kobayashi et al. 1999; Minamino et al. 1995). The 
phorbol ester TPA also stimulated adrenomedullin production in endothelial 
cells, suggesting that adrenomedullin production may at least in part be regulated 
by PKC (Isumi et al. 1998). 
The regulation of PAMP has been studied less than that of 
adrenomedullin. At this time it is not known if both of the products of the 
adrenomedullin gene are produced in equal amounts or if their transcription is 
independently or differentially regulated. 
5.2 ACTIONS 
When first identified both adrenomedullin and PAMP were described as 
hypotensive peptides (Kitamura et al. 1993; Kitamura et al. 1994). However, it 
is now known that the role of these two peptides extends well beyond this. 
Adrenomedullin has been shown to play a role in cell growth (Kapas et al. 1997), 
natriuresis (Charles et al. 1997; Jorgasaki et al. 1995) and regulation of hormone 
secretion as well as exhibiting anti-microbial properties (Allaker et al. 1999). 
However, only the actions of adrenomedullin and PAMP in the regulation of 
steroid secretion from the adrenal gland will be discussed here. For other actions 
of adrenomedullin and PAMP see reviews (Samson 1998 and 1999; Charles 
1999; Hinson et al. 2000). 
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5.2.1 ADRENAL 
The reported actions of adrenomedullin and PAMP in the adrenal gland are 
somewhat contradictory, depending at least in part on the tissue preparation used. 
Studies using collagenase-dispersed adrenal zona glomerulosa cells from both rat 
and human reported that adrenomedullin had an inhibitory effect on All- 
stimulated aldosterone secretion (Andreis et al. 1997 a and b). These inhibitory 
actions were however blocked in the presence of CGRPS. 37, a CGRP receptor 
antagonist, indicating that adrenomedullin was not acting through a specific 
adrenomedullin receptor but through the CGRP-1 receptor. Adrenomedullin has 
also been shown to stimulate aldosterone secretion in intact rat capsular tissue, 
collagenase-dispersed rat zona glomerulosa cells (Hinson et al. 1998) and human 
adrenal slices (Andreis et al. 1997). Stimulation of aldosterone secretion by 
adrenomedullin was not attenuated by CGRP8.37. Thus it appears that, with 
regard to aldosterone secretion, when acting through the CGRP-1 receptor the 
effect of adrenomedullin is opposite to that exhibited when acting through a 
specific receptor. Adrenomedullin was also reported to cause an increase in 
aldosterone secretion in the isolated perfused in situ rat adrenal gland (Mazzocchi 
et al. 1996). This study also reported an increase in corticosterone secretion and 
in perfusion medium flow rate. PAMP was shown to be without effect on basal 
or ACTH-stimulated aldosterone secretion in both rat and human dispersed zona 
glomerulosa cells, but did inhibit All-stimulated aldosterone secretion in both 
tissues (Andreis et al. 1997; Neri et al. 1997). 
The effects of adrenomedullin and PAMP on cortisol secretion are also 
somewhat unclear. Neither PAMP nor adrenomedullin had any effect on cortisol 
secretion from dispersed human adrenocortical cells (Andreis et al. 1998). 
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However, infusion of adrenomedullin into conscious sheep caused a significant 
decrease in cortisol secretion (Parkes and May 1995). This may not have been a 
direct effect, as this study also reported a decrease in ACTH after administration 
of adrenomedullin. Both adrenomedullin and PAMP have also been shown to 
inhibit ACTH secretion from pituitary cells (Samson et al. 1995). 
Both adrenomedullin and PAMP are also located in the adrenal medulla 
and are known to be co-secreted with catecholamines (Katoh et al. 1994 and 
1995). Adrenomedullin does not alter catecholamine secretion (Houchi et a!. 
1996). PAMP however, has been shown to inhibit catecholamine synthesis in 
cultured bovine adrenal medullary cells (Katoh et a!. 1995; Niina et al. 1995). 
5.3 ADRENOMEDULLIN RECEPTORS 
The actions of adrenomedullin were at first thought to be mediated via the CGRP 
type-1 receptor, as many of the actions of adrenomedullin mimicked those of 
CGRP and these were blocked by the CGRP-1 receptor antagonist CGRP8.37. 
The vasodilator effects of adrenomedullin on the rat mesenteric vascular bed and 
isolated rat heart preparation were blocked by CGRP8.37 (Nuki et al. 1993; 
Entzeroth et al. 1995). Adrenomedullin was later shown to bind with low affinity 
to the CGRP-1 receptor (Aiyar et al. 1996). However, not all of the actions of 
adrenomedullin can be accounted for by binding to the CGRP-1 receptor. 
Specific adrenomedullin receptors were demonstrated by binding of 1231- 
adrenomedullin in rat VSMC (Eguchi et al. 1994). These receptors showed very 
poor affinity for CGRP. Specific binding sites for l "I-adrenomedullin were then 
demonstrated in several tissues in the rat including heart, lung, spleen and liver 
(Owji et al. 1995). It was therefore apparent that adrenomedullin could function 
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through at least one other receptor. There are currently two candidate 
adrenomedullin receptors, L1 and CRLR/ RAMP-2. 
L1 was originally identified from rat lung and was classified as an orphan 
receptor (Eva & Sprengel 1993). The cDNA encoded a 395 residue polypeptide 
which was structurally similar to a seven transmembrane G-protein coupled 
receptor. This receptor was later shown to be expressed in several tissues, 
including the adrenal, heart, lung and spleen (Kapas et al. 1995). When 
transfected into COS-7 cells this receptor specifically bound 1251-adrenomedullin 
and elevated cAMP in response to adrenomedullin (Kapas et al. 1995). Human 
L1, which exhibited 73% homology to rat L1, was later cloned (Hanze et al. 
1997). Recently however, there has been some doubt as regards the authenticity 
of human and rat L1 as an adrenomedullin receptor. A recent study reported no 
125I-adrenomedullin binding or elevation of cAMP in COS-7 cells transfected 
with human and rat L1 (Kennedy et al. 1998). 
The second candidate adrenomedullin receptor, CRLR was first cloned in 
the rat by Njuki et al. (1993) using primers based on porcine calcitonin receptor. 
Human CRLR was then cloned by Fluhmann et al. (1995). Human CRLR shows 
a high degree of homology to rat CRLR. However, CRLR was initially 
considered to be an orphan receptor as when transfected into COS-7 cells it did 
not bind any member of the CGRP peptide superfamily (Fluhmann et al. 1995). 
Human CRLR did however bind CGRP, and adrenomedullin to a lesser extent, 
when transfected and expressed into HEK 293 cells (Aiyar et al. 1996). The 
reason for this selective binding was later found to be due to the presence of 
receptor-activity modifying proteins (RAMPS) which are a family of single- 
transmembrane domain proteins with an extracellular N terminus and a 
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cytoplasmic C terminus (McLatchie et al. 1998). RAMPs are required to 
transport CRLR to the plasma membrane and confer specificity to CRLR once in 
place. CRLR does not bind in the absence of RAMPs and vice versa. To date 
three RAMPs have been identified, RAMP-1,2 and 3 (McLatchie et al. 1998). 
CRLR, when complexed with RAMP-1, acts as a receptor for CGRP and does 
not bind adrenomedullin. The CRLR/RAMP-2 complex however, binds 
adrenomedullin and not CGRP (McLatchie et al. 1998; Kamitani et al. 1999). 
The CRLR/RAMP-3 complex also functions as an adrenomedullin receptor 
although there may be another, as yet unidentified, function of the CRLR/RAMP- 
3 complex. 
To date, no specific PAMP receptor has been identified. However, 
specific PAMP binding sites have been located in a variety of tissues including 
adrenal, aorta, kidney and lung in the rat and also in cultured rat vascular smooth 
muscle cells (Iwasaki et al. 1996). In this study PAMP was also shown to bind 
specifically to a 90 kDa protein (Iwasaki et al. 1996). The actions of PAMP are 
not blocked by CGRPg. 37 or adrenomedullin, suggesting the existence of a 
specific receptor. However, PAMP binding which is displaced by PAMP12-2o has 
been reported (Belloni et al. 1999). Therefore, PAMP12-20 may function as a 
specific antagonist for the PAMP receptor. 
5.4 MECHANISMS OF ACTION 
Despite both adrenomedullin and PAMP being cleavage products of the same 
gene and both exerting a hypotensive effect their mechanisms of action are 
different. The main mechanism by which adrenomedullin exerts its effect is by 
activation of adenylyl cyclase, resulting in an increase in cAMP. Many studies, 
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in a variety of tissues and cells have reported an increase in cAMP in response to 
adrenomedullin (see reviews; Samson 1998; Kangawa et al. 1996). Of the 
known receptors to which adrenomedullin will bind, L1, the CRLR/RAMP-2 
complex and CGRP type 1 receptor, all are associated with cAMP stimulation 
(Kapas et al. 1995; McLatchie et al. 1998; Aiyar et al. 1996). Adrenomedullin 
has also been shown to increase Ca2+ via a cholera toxin sensitive mechanism 
independently of cAMP increase (Shimekake et al. 1995). In this study increase 
in Ca2+ was accompanied by an increase in inositol trisphosphate both of which 
were attenuated in the presence of a phospholipase C (PLC) inhibitor, indicating 
that Ca2+ accumulation in response to adrenomedullin had been due to activation 
of PLC. An increase in cGMP as a result of nitric oxide synthase activation in 
response to adrenomedullin was also reported in this study. However, this effect, 
of adrenomedullin stimulating two independent signal transduction pathways 
simultaneously does not appear to be universal. A study in bovine endothelial 
cells reported an increase in cAMP but not Ca2+ in response to adrenomedullin 
(Barker et al. 1996). Similarly, in Swiss 3T3 cells cAMP was increased in 
response to adrenomedullin, without effect on Ca2+ (Withers et al. 1996). 
However in a study in the perfused rat heart Ca2+ was increased in response to 
adrenomedullin while cAMP remained unaltered (Szokodi et al. 1998). In 
addition to stimulating these two signalling pathways adrenomedullin has also 
been reported to have an effect on mitogen-activated protein kinase (MAPK) 
activity. In vascular smooth muscle cells (VSMC) adrenomedullin increased 
MAPK activity by a cAMP-independent mechanism (Iwasaki et al. 1998). 
However, in rat-2 fibroblasts adrenomedullin increased cAMP and inhibited 
MAPK activity (Coppock et al. 1999). A recent study has shown that K+-ATP 
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channels are activated by adrenomedullin (Sakai et at 1998). It is clear from this 
that adrenomedullin is capable of activating a variety of signal transduction 
pathways in different cell types although the exact mechanism by which each 
pathway is activated in various cells as yet remains unclear. 
While many studies have reported an elevation in cAMP in response to 
adrenomedullin no such similar effect of PAMP has been reported. PAMP was 
shown not to alter cAMP levels in C6 glioma cells (Moody et al. 1997). In the 
adrenal medulla PAMP inhibits catecholamine synthesis. In cultured bovine 
adrenal medullary cells PAMP inhibited carbachol-induced catecholamine 
synthesis (Niina et al. 1995). This is likely to be mediated via suppression of 
nicotinic receptors, which are involved in catecholamine synthesis, as in a later 
study PAMP was shown to suppress these receptors in the rat locus coeruleus 
(Nabekura et al. 1998). This action of PAMP also attenuates nicotine-induced 
rises in Ca2+ (Nagatomo et al. 1996). PAMP also alters Ca2+ levels by inhibition 
of N-type Ca2+ channels, this inhibitory effect is however reversed by pertussis 
toxin (Takano et al. 1996). PAMP also inhibits noradrenaline overflow from 
nerve endings, an effect which is also attenuated by pertussis toxin (Shimosawa 
et al. 1995). While the mechanism of action of PAMP has not yet been fully 
clarified it would appear that PAMP to mediates its affect through a pertussis 
toxin sensitive G-protein coupled receptor (Shimosawa et al. 1997). 
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6 METHODS USED TO STUDY ADRENOCORTICAL FUNCTION 
There are many different techniques, both in vivo and in vitro, available to study 
adrenocortical function. All of which have advantages and disadvantages. 
6.1 TISSUE 
There is an obvious ethical disadvantage associated with animal work. In 
addition to this, reproducibility of results obtained with fresh tissue can also be a 
problem. Also, while rat tissue is readily available human tissue is difficult to 
obtain and very variable. Both of these factors would make it desirable to have a 
steroid secreting cell line. 
Additionally, the method of tissue preparation used can also affect the 
results obtained. While both intact adrenal tissue and dispersed adrenal cells 
secrete steroids, their response to stimuli and rate of steroid secretion are not the 
same (Vinson et al. 1985). Enzymatic digestion of cells to create a dispersed cell 
population may affect cell surface receptors and cause response to stimuli to be 
altered. Also with both of these preparations, vasculature and innervation are not 
preserved. Steroid secretion from the adrenal gland can be studied with the 
vasculature and innervation intact by using the in situ isolated perfused adrenal 
gland (Hinson et al. 1985). 
Primary cultures of adrenal cells are also used to study adrenal function. 
However, a continual supply of fresh tissue is required as adrenal cells in long 
team primary culture loose their ability to secrete the normal range of steroids 
(Hornsby and Gill 1981). 
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6.2 ADRENAL CELL LINES 
The in vitro study of adrenocortical function would be greatly enhanced by an 
adrenocortical cell line, which maintained the ability to secrete the major adrenal 
steroids and responded to the known regulators of steroid production, i. e. ACTH, 
All and K. Until recently, the in vitro study of adrenocortical function relied on 
the use of primary cell culture, which requires a continual supply of fresh tissue, 
or the Y1 mouse adrenal cell line (Yasamura et al. 1966). These cells however 
do not express 21-hydroxylase, or being of rodent origin, 17-hydroxylase, and 
although they respond to ACTH they exhibit little response to All or K. They 
also do not secrete the normal adrenal steroids. 
Several attempts to develop a human adrenal cell line have been made. 
Leibovitz et al. (1973) characterised the SW13 cells these however were did not 
retain the ability to produce steroids. Cheng et al. (1992) attempted to create a 
human adrenal cell he by using viral oncogenes to immortalise human foetal 
adrenocortical cells. The resulting cells however did not produce either 
mineralocorticoids or glucocorticoids. Attempts to create a human adrenocortical 
cell line using adrenocortical tumours were difficult due to the relative rarity of 
steroid hormone producing adrenocortical tumours which secrete the main 
adrenocortical steroid hormones, both mineralocorticoid and glucocorticoid. 
6.2.1 THE NCI-H295 CELL LINE 
The NCI-11295 cell line is a human adrenocortical cell line which was first 
described in 1990 by Gazdar et al. The cell line had been established from a 
primary invasive adrenocortical tumour. Steroid analysis of the cells was carried 
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out after the cells had been in culture for 7-10 years. Initial analysis of the cell 
culture medium by gas chromatography/mass pectroscopy revealed the presence 
of more than 30 steroids of which about 20 were identified. The presence of this 
range of steroid hormones also suggested that the H295 cells produced the major 
steroidogenic enzymes. The presence of these steroidogenic enzymes was 
confirmed by mRNA analysis which revealed the presence of CYPIIA, 
CYP11B1, CYP11B2, CYP17 and CYP21 (Bird et al. 1993; Holland et at. 1993; 
Rainey et al. 1993; Staels et al. 1993). Therefore, the NCI-11295 cell line 
represents the first cell line to maintain the ability to secrete all major adrenal 
steroids. It is of added advantage that these cells are of human origin rather than 
rodent and therefore also produce 17-hydroxylase and subsequently cortisol and 
the adrenal androgens. 
Another advantage of the NCI-H295 cell line is that it responds well to 
the physiological regulators of steroid secretion in the adrenal cortex, with the 
exception of ACTH. Aldosterone secretion was shown to increase in a dose- 
dependent manner in response to All, with a maximal effect being observed at 
IOnM (Bird et al. 1993). Aldosterone secretion was also shown to increase in 
response to K+, with a similar increase to that observed in the presence of All at a 
concentration of 16mM. Binding studies using radiolabelled All revealed that in 
this cell line the predominant All receptor was the type 1 receptor (Bird et al. 
1993). In vivo aldosterone secretion is not solely regulated by All and K+ but 
also by other factors. Some of these other factors have also been shown to be 
expressed by H295 cells. Parathyroid hormone, which acts to stimulate 
aldosterone secretion in the zona glomerulosa also stimulates aldosterone 
secretion in the H295 cell line (Hanley et al. 1993). 
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In the adrenal cortex the main physiological regulator of steroid secretion 
from the inner zones is ACTH. However, in the H295 cell line ACTH receptor 
mRNA expression is low and subsequently response to ACTH is poor (Mountjoy 
et al. 1994). These cells however, respond well to other activators of the protein 
kinase A pathway, namely forskolin and dbcAMP, both of which cause a dose 
dependent increase in cortisol secretion (Rainey et al. 1993). DHEA secretion is 
also greatly increased in the presence of forskolin or dbcAMP, but this 
stimulatory effect is essentially knocked out with activation of the protein kinase 
C pathway (Rainey et al. 1993). 
a. substrains of the NCI-H295 cell line 
The original strain of NCI-H295 cells grows as a loosely aggregated suspension 
and has a relatively long population doubling time of 5 days. From this cell line 
two substrains have been established by similar methods, both of which grow as 
an adherent monolayer with reduced population doubling time. The first of these 
strains to be established was designated H295R cell line to distinguish it from the 
original cell line (Rainey et al. 1994). It is this strain which is most widely used. 
The second substrain of the NCI-H295 cell line to be established was designated 
H295A (Rodriquez et al. 1997). However, the steroidogenic and hormonal 
response of these cells has not been described, to date. 
b. steroidogenesis in the H295R cell line 
Production of the steroidogenic enzymes by H295R cells are in response to the 
culture conditions. The fact that these cells produce steroidogenic enzymes 
common to all three zones of the adrenal cortex, whose expression can be 
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manipulated, would suggest that the H295R cell line is a pluripotent 
adrenocortical cell line. 
The ratio of 30-HSD to CYP17 is one of the defining characteristics by 
which zone specific steroid hormone production is achieved in the adrenal gland. 
In the glomerulosa, where no CYP17 is expressed and high levels of 3ß-HSD are 
found the metabolism of pregnenolone to 17-hydroxypregnenolone is prevented, 
thus preventing production of cortisol, while conversion to progesterone and 
subsequently aldosterone is promoted. The opposite of this occurs in the zona 
fasciculata, where high levels of CYP17 are produced, thus preventing the 
formation of progesterone and promoting the formation of 17- 
hydroxypregnenolone through which cortisol is produced. Aldosterone synthase 
is produced predominantly in the zona glomerulosa and is essential for the 
formation of aldosterone while CYP11B1 is produced exclusively in the zona 
fasciculata and is essential for the formation of cortisol. Both of these enzymes 
are found in H295R cells and their expression can also be regulated by altered 
culture conditions. Treatment of the cells with activators of the protein kinase A 
pathway increases both CYP 11 B2 and CYP 11 B1 however, a much greater effect 
is observed on CYP11B1 (Staels et al. 1993). Treatment of these cells with All 
causes a marked increase in CYP 11 B2 expression (Bird et al. 1993). 
60 
Chapter 1: Introduction and Literature Review 
7 OBJECTIVES OF THIS STUDY 
The main aims of this study were two-fold. Firstly to determine the effect of 
PAMP in the rat adrenal gland and secondly to determine the effect of both 
PAMP and adrenomedullin in the human adrenocortical tumour cell line, H295R. 
Previous studies from this laboratory had shown that the rat adrenal zona 
glomerulosa expressed the adrenomedullin gene, and had demonstrated the 
effects of adrenomedullin on zona glomerulosa function. It was not clear, 
however, whether PAMP also had an effect on the rat zona glomerulosa. The 
present studies were designed to address this question. 
The second aim of the study was to determine whether human 
adrenocortical cells produced adrenomedullin gene products, whether the 
expression of the gene was actively regulated, and to examine the effects of 
adrenomedullin and PAMP on human adrenocortical cell function. 
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MATERIALS AND METHODS 
1 MATERIALS 
a. Animals 
All rats used in the following experiments were female Wistar rats (body weight 
250-350 g) obtained from the colony maintained at Queen Mary and Westfield 
College and were allowed free access to food and water. All animal 
experimentation and management was conducted with appropriate Home Office 
licensing arrangements. 
b. Peptides 
Adrenomedullin (human 1-52 and rat 1-50), PAMP (human and rat), CGRP-1 
(human and rat) and amylin (rat) were purchased from Phoenix Pharmaceuticals 
(Mountain View, CA, USA). ACTH 1-24 (Synacthen) was obtained from Ciba- 
Geigy (Horsham, Surrey, UK). Angiotensin-II was purchased from Sigma- 
Aldrich (Poole, Dorset, UK). 
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c. Solvents 
All solvents were obtained from Merck-BDH (Poole, Dorset, UK). 
d. Radiochemicals 
[125I]-PAMP was purchased from Phoenix Pharmaceuticals (Mountain View, 
CA, USA). [1,2,6,7-3H]-aldosterone, [2,8-3H1-adenosine 3', 5'-cyclic phosphate 
and cortisol-3-(O-carboxymethyloximino-(2-[125I]iodohistamine) were purchased 
from Amersham Pharmacia Biotech (St Albans, Herts, UK). 
e. Tissue Culture Medium and Supplements 
H295R cells were obtained from Professor William Rainey (Southwestern 
Medical Center, Dallas, Texas, USA) and Professor Ian Mason (Royal Infirmary 
of Edinburgh, Edinburgh, UK). All tissue culture medium and supplements were 
purchased from Life Technologies (Paisley, UK) with the exception of +1 ITS 
medium supplement which was purchased from Universal Biologicals (Glos., 
UK). 
f. RNA Extraction, cDNA Synthesis and PCR 
Ultraspec 1 step RNA extraction system was purchased from AMS 
Biotechnology UK Ltd, (Whitney, UK). All reagents required for cDNA 
synthesis were purchased from Life Technologies (Paisley, Scotland). For PCR, 
all reagents were purchased from Life Technologies (Paisley, Scotland) with the 
exception of Taq DNA polymerase which was purchased from AB 
Biotechnology (Cambridge, UK), agarose which was purchased from GibcoBRL 
(Renfrew, UK). The primers were all purchased from GibcoBRL (Renfrew, 
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UK), with the exception of the primers for L1 which were purchased from 
MGW-Biotech (Germany). 
g. Immunocytochemistry 
All reagents used for immunocytochemistry were purchased from Dako 
(Cambridge, UK) with the exception of the Vector Red Staining Kit, which was 
purchased from Vector Laboratories (Peterborogh, UK). The antibodies were 
raised to peptide sequences coupled to keyhole limpit haemotoxylin (KLH) in 
rabbits, with the exception of the PAMP antibody which was obtained from Drs. 
Martinez and Cuttitta (NIH, Bethesda, Maryland, USA). The peptides that the 
antibodies were raised against are as listed in table 2.3. 
h. Assay Kits 
Adrenomedullin (1-52, human) and PAMP enzyme immunoassay kits were 
purchased from Phoenix Pharmaceuticals (Mountain View, CA, USA). DHEA 
radioimmunoassay kits were purchased from EuroDPC (Llanberis, UK). 
i. Other Reagents 
All other reagents were obtained from Sigma-Aldrich (Poole, Dorset, UK) with 
the exceptions of HA1004 which was purchased from Semat Laboratories (St 
Albans, Herts., UK), collagenase (Worthington type 1) which was purchased 
from Lorne Laboratories (Reading, UK) and the cortisol antibody which was 
purchased from Bioclinical Services (Cardiff, UK). 
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2 METHODS (Tissue) 
2.1 TISSUE PREPARATION 
Rats were rapidly killed by mechanical stunning followed by cervical dislocation. 
The adrenal glands were removed and stored in Krebs bicarbonate buffer (table 
2.1) on ice for periods of less than 20 minutes before the capsule, to which the 
zona glomerulosa cells remain attached, was separated from inner zones/ medulla 
by gentle compression between glass plates. These capsules were then incubated 
as described below or used to make a cell preparation. 
To obtain a glomerulosa cell preparation, capsules were incubated in 
Krebs bicarbonate buffer containing 2 mg/ml collagenase at 37°C for 60 minutes 
under 95 % 02/ 5% CO2. After this incubation, tissue was dispersed by repeated 
pipetting and filtered through a nylon gauze. Dispersed cell suspensions were 
centrifuged at 100g for 15 minutes at 4°C and the resulting supernatant 
discarded. The pelleted cells were then resuspended in Krebs bicarbonate buffer 
to a concentration which would result in 10 000 cells/ tube in subsequent 
experiments. 
2.2 ALDOSTERONE SECRETION 
Rat adrenal capsule tissue preparations and dispersed zona glomerulosa cells 
were prepared as described above. PAMP was dissolved in Krebs bicarbonate 
buffer to give concentrations of 100 pmol/l -1 pmolA. Individual rat adrenal 
capsules or dispersed zona glomerulosa cells were then incubated in the absence 
or presence of increasing concentrations of PAMP at 37°C for 60 minutes under 
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TABLE 2.1: KREBS BUFFER BICARBONATE BUFFER 







THE BUFFER WAS GASSED WITH 95 % 02/ 5% CO2 TO BRING THE pH TO 7.4.0.2 % 
(w/v) GLUCOSE AND 0.2 % (w/v) BSA (FRACTION V) ADDED. 
95 % 02/ 5% CO2. At the end of the incubation either the capsules were 
removed or the cells were pelleted by centrifugation, 10 000 rpm for 5 minutes at 
4°C and the supernatant removed to a fresh tube and stored at -20°C until 
assayed for aldosterone. This experiment was carried out in duplicate and 
repeated three times. 
2.3 cAMP RELEASE 
Rat adrenal capsules and dispersed zona glomerulosa cells were prepared and 
incubated, in the absence and presence of increasing concentrations of PAMP, as 
described above. In addition, capsule tissue was incubated in either PAMP (100 
nmol/1) or ACTH (1 nmol/1) in the absence or presence of HAI 004 (1 µmoVl), a 
selective inhibitor of protein kinase A, as described above. At the end of the 
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experiments either the capsule was removed or the cells pelleted by 
centrifugation at 10 000 rpm for 5 minutes at 4°C and the supernatant removed to 
a fresh tube and stored at -20°C until assayed for cAMP. These experiments 
were carried out in duplicate and repeated three times. 
2.4 CATECHOLAMINE RELEASE 
Catecholamine release was measured by assaying the total adrenaline and 
noradrenaline content of incubation medium from intact rat adrenal capsules by a 
method based on the trihydroxyindole florescence method of Brocklehurst and 
Pollard (1990). The technique involves the oxidation of catecholamines by 
K2Fe(CN)6 and the subsequent generation of the trihydroxyindole flourophore 
product by NaOH and ascorbic acid. The oxidation reactions were performed 
under both acidic and neutral pH conditions to allow measurement of adrenaline 
and noradrenaline. Intact rat adrenal capsules were prepared and incubated in 
Krebs bicarbonate buffer in the absence and presence of PAMP (100 nmol/1) for 
1 hour at 37°C, as described above. After the incubation the capsules were 
removed and the incubation medium assayed. Two sets of duplicate labelled 
tubes were set up containing 50 µd of sample. To one set of tubes 500 µl sodium 
phosphate buffer (pH 7.0) was added and to the other set 500 pl of 10 % (v/v) 
acetic acid was added. 50 tl of K2Fe(CN)6 was added to all tubes, which were 
the incubated on ice for 20 minutes. The reaction was terminated by the addition 
of 1 ml 9 mol/1 NaOH containing 0.4 % ascorbic acid (w/v), followed by 
vortexing. The trihydroxyindole fluorescence product was measured after the 
addition of 2 ml water in a spectrofluorimeter (Luminescent fluorimeter LS-50B, 
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Perkin Elmer, Warrington, UK) with an excitation wavelength of 412 nm and an 
emission wavelength of 523 nm. 
2.5 1251-PAMP BINDING ASSAY 
Rat adrenal capsule tissue, prepared as described above, was preincubated for 60 
minutes in KREBS buffer (containing 20 mM HEPES and 1 mmol/l EDTA). 
After preincubation capsules were homogenised in incubation buffer (as for 
preincubation buffer plus 150 mM NaCl and 1 pg/ml each of aprotonin and 
soybean trypsin inhibitor). 50 µl 125I-PAMP (2 000 Ci/mmol: final concentration 
0.1 nmol/1) was added to aliquots of homogenate containing increasing 
concentrations of cold peptide (10 pmol/1-1 pmol/1, plus 5 pmol/l to determine 
non-specific binding) for 60 minutes at room temperature. The reaction was 
terminated by the addition of 800 µl ice cold incubation buffer. The tubes were 
then centrifuged at 10 000 rpm at 4°C for 5 minutes. The pellets were washed a 
further twice with ice-cold incubation buffer and the remaining supernatant 
aspirated. The pellets were counted for 3 minutes using a LKB-Wallac 
CliniGamma 1272 gamma counter (Wallac oy, Finland). All incubations were 
carried out in triplicate and repeated at least three times. Protein content of the 
homogenates was determined using the method of Bradford (1976). Binding data 
was analysed using LIGAND (Munson and Robard, 1980). 
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3 METHODS (H295R Cell Line) 
H295R cells were routinely maintained in 75 cm2 tissue culture flasks in 
DMEM/F12 medium supplemented with 2% (w/v) Ultroser G, insulin (6.25 mg), 
transferrin (6.25 mg), selenium (6.25 mg), linoleic acid (5.35 mg: as 1% (v/v) 
ITS), 1% penicillin/ streptomycin and 1% fungizone at 37°C under an 
atmosphere of 95 % air/ 5% CO2. Cells were passaged 1: 3 using a solution of 
trypsin/EDTA and took approximately 6 days to reach confluency. All cells used 
for the experiments were between passages 10 and 30. 
3.1 PRE-TREATMENT OF CELLS 
Cells were cultured in either 6 well plates (for treatment with peptides) or 75 cm2 
tissue culture dishes (for RNA extraction) and were then pre-treated for 48 hours 
in the above tissue culture medium containing either no agonist (control), All (10 
nmol/1), forskolin (10 pmol/1), adrenomedullin (100 nmol/1) or PAMP (100 
nmol/1) as stated. The medium was replaced every 24 hours and aliquots stored 
at -20°C, for radioimmunoassay for aldosterone, cortisol and DHEA. Control, 
All and forskolin pre-treatment medium were also assayed for adrenomedullin 
and PAMP. 
3.2 RNA EXTRACTION. cDNA SYNTHESIS AND PCR 
Total RNA was isolated using ultraspec 1 step solution following the 
manufacturers instructions. Purity of the RNA was estimated by measuring the 
optical density at 260/280 nm. 5µg of total RNA was subjected to first-strand 
cDNA synthesis in a 20 pl reaction volume containing 250 mM Tris-HC1 (pH 
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8.3), 375 mM KCI, 15 mM MgCI2,1 mM of each dNTP, 20 U RNase inhibitor, 
in the presence of 1.5 pg oligo dT(12.18) primer and 200 U supcrscriptase. After 
completion of first- 
strand cDNA synthesis the reaction was stopped by heat inactivation (95°C for 5 
minutes) and diluted to 50 ng/µl RNA equivalents with water. cDNA amounts 
equivalent to 100 ng of total RNA were then subjected to PCR in a 50 µl reaction 
volume containing 10 mM Tris-HCI (pH 9), 1.5 mM MgCl2,200 pM of each 
dNTP, 1 pM of each primer and 0.2 U of Taq DNA polymerase under the 
following conditions: 1 cycle of denaturation at 94°C for 5 minutes; 35 cycles of 
denaturation for 1 minute at 94°C, 1 minute primer annealing at calculated 
temperature (see table 2.2), 1 minute primer extension at 72°C; 1 cycle of primer 
extension for 10 minutes at 72°C. 10 µl of the PCR products were 
electrophoresed through ethidium bromide stained 1% agarose gels and viewed 
by UV illumination. Primers used were as listed in table 2.2. The integrity of the 
cDNA was tested by PCR for glyceraldehyde-3 -phosphate dehydrogenase 
(GAPDH), the resulting products can be seen in figure 2.1. 
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TABLE 2.2: PRIMER DATA FOR RT-PCR 
PCR NUCLEOTIDE ANNEALING 
GENE SEQUENCE PRODUCT (bp) POSITION TEMP. (°C) 
GAPDH 5'-acc aca gtc cat gcc atc ac-3's 490 +465 64 
5'-tcc acc acc ctg ttg ctg ta-3'as +955 
AM 5'-agt caa gcg cta ccg cca ga-3's 1020 +3010 65 
5'-gtt tgc tgt tcg cat atc acc c-3'as +4030 
PAMP 5'-ttt cca ggg tct gcg ctt cg-3's 277 +2327 64 
5'-ctg tct tcg ggg ctt cga ga-3'as +2753 
Ll 5'-ggt cac gct gga cta cac ct-3's 500 +336 58 
5'-agc agg gtc aca tga tag gg-3'as +836 
CRLR 5'-cct gag gac tca att cag tt-3's 805 +552 58 
5'-cca tgg ata atg tag agg ag-3'as +1357 
RAMP-1 5'-cca gtt cca ggt aga cat g-3's 311 +158 59 
5'-ccc tca gtg cgc ttg ctc-3' as +469 
RAMP-2 5'-tgg atc cta tcg aaa agg-3's 290 +295 53 
5'-cct cac tgt ctt the tcc-3'as +585 
30-HSDII S'-aag ctg aca gtg ctg gaa gg-3's 370 +615 51 
5'-gga tcc cat tgt tgt tga gg-3'as +1109 
CYP 11 B2 5'-cct gaa tgg cgc ttc aac-3's 802 +2915 60 
5'-cct caa agt gct cct tcc-3' as +3717 
CYP17 5'-gcc ata tgc ata aca act tc-3's 157 +181 59 
5'-cat ttg agg ccg ccc aga ga-3'as +338 
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Figure 2.1: RT-PCR showing expression of GAPDI 1. 
}{295R cells were incubated for 48 hours prior to RNA 
extraction with AM (100 nmol/1), PAMP (100 nmol/1), All 
(10 nmol/1) or forskolin (10 µmol/l). 
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3.3 IMMUNOCYTOCHEMISTRY 
Cells which had not been pre-treated were seeded onto sterile covcrslips in 24 
well plates at cell densities of 30 000 and 60 000 cells/well. Cells were then 
maintained overnight in complete DMEM/F12 medium to allow attachment of 
the cells to the coverslips. Cells were then washed in triplicate with sterile PBS 
between each stage unless otherwise stated. When the cells had sufficiently 
attached to the coverslip they were fixed with 3.7 % paraformaldehyde pH 7.4 at 
4°C for 5 minutes. Cells were then incubated for 5 minutes in a freshly made 
solution of 1% triton x100 in PBS to permeablise the cells. Primary antibody or 
primary antibody plus antigen, at dilutions stated in table 2.3 were added to each 
well and left overnight at 4°C in moist conditions. The following day, primary 
antibody was removed and 250 µl of 1: 200 dilution of biotin anti-rabbit 
conjugate, which had been prepared 30 minutes prior to use, was added to each 
well and incubated for 30 minutes at room temperature. After this 250 µl of 
avadin alkaline phosphatase, which had also been prepared 30 minutes prior to 
use in tris buffer pH 7.6, was added to each well and incubated at room 
temperature for 30 minutes. Each well was then washed once with PBS, three 
times with tris buffer pH 7.6 and once with tris buffer pH 8.2 for 5 minutes 
before being incubated at room temperature for 25 minutes in vector red solution. 
The vector red solution was made up immediately before use in tris buffer pH 8.2 
containing 0.1 % levamisol. Each well was then washed in distilled H2O for 10 
seconds and then 250 µl Mayers hemaotoxylin for 1 minute to counterstain the 
nuclei. The coverslips were then carefully removed from the 
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TABLE 2.3: ANTIBODY DATA FOR IMMUNOCYTOCHEMISTRY 
AMINO ACIDS SEQUENCE DILUTION 
AM 26-39 LAIUQIYQFTDKDKD 1: 1000 
LI 238-253 ACRLRRQGQTESRRHC 1: 1600 
CRLR 90-114 DYFQDFVPSEKVTKICDQDGNWFRHP 1: 1200 
wells, washed twice in 100 % ethanol and once in xylene, then mounted using a 
xylene based mountant. 
3.4 STEROID SECRETION 
a. To determine the effect of adrenomedullin and PAMP on steroid 
secretion, cells which had not been pre-treated were cultured in 6 well plates and 
maintained overnight in ITS and Ultroser-free medium then washed twice with 
PBS before being incubated for 4 hours at 37°C with either no agonist (control), 
adrenomedullin (10 pmol/l -1 pmol/l) or PAMP (10 pmol/l -1 µmol/1). At the 
end of the incubation period the medium was removed to fresh tubes and stored 
at -20°C for radioimmunoassay for aldosterone, cortisol and DHEA. Cells were 
harvested and the protein content determined (Lowry et a!. 1951). This 
experiment was carried out in triplicate and repeated four times. 
b. To determine whether the effect of adrenomedullin and PAMP was 
altered after pre-treatment cells were cultured in 6 well plates and pre-treated for 
48 hours as described above with either no agonist (control), All (10 nmol/1) or 
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forskolin (10 pmoUl). After pre-treatment, cells were washed twice with PBS 
and incubated in incubation medium (DMEM/F12 as above minus ITS and 
Ultroser G) and at 37°C for 4 hours with either no agonist (control), 
adrenomedullin (100 nmol/1), PAMP (100 nmol/1), All (10 nmol/l), ACTH (1 
nmol/1) or forskolin (10 pmol/1). At the end of the incubation the medium was 
removed to fresh tubes and stored at -20°C for radio immunoassay for 
aldosterone, cortisol and DHEA. The cells were harvested and the protein 
content was determined (Lowry et al. 1951). This experiment was carried out in 
triplicate and repeated 4 times. 
3.5 cAMP RELEASE 
a. In order to determine the optimum incubation time for cAMP formation a 
time course was set up using either adrenomedullin (100 nmol/1) or PAMP (100 
mmol/l) at 5 minute intervals for 60 minutes. H295R cells were cultured in 6 well 
plates with no pre-treatment as described above. The cells were maintained in 
Ultroser-G free, ITS-free medium overnight, prior to incubation. The cells were 
then washed three times in the Ultroser-G free, ITS-free medium, containing 0.5 
mmol/l IBMX. The cells were then incubated at 37°C in this medium ± peptide 
at 5-minute intervals for 60 minutes. The reaction was arrested by placing the 
samples on ice. The cells were harvested from the plates and the cells/ medium 
was transferred to fresh eppendorf tubes, which were heated to 90°C for 15 
minutes to lyse the cells. The samples were freeze dried and reconstituted in 100 
pl of cAMP assay buffer. 50 µ1 was assayed, in duplicate, using a cAMP binding 
protein assay. Figure 2.2a and b show the cAMP formation over time in response 
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to a single concentration of adrenomedullin and PAMP. As can be seen from 
these data, peak formation of cAMP was at 20 minutes for both adrenomedullin 
and PAMP. This experiment was carried out in triplicate and repeated twice. 
b. To determine the response of cAMP to adrenomedullin and PAMP 
H295R cells were cultured as for the time course and incubated at 37°C for 20 
minutes with either no agonist (control), forskolin (10 pmol/1), adrenomedullin 
(10 pmol/l -1 pmol/1) or PAMP (10 pmol/1-1 pmol/1). Cells were harvested and 
assayed as described above. Experiments were carried out in triplicate and 
repeated 4 times. 
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FIGURE 2.2: Time course of cAMP release in response to a) 
adrenomedullin (100 nmol/1) and b) PAMP (100 nmol/1). 
Data shown are mean ± SEM, n=6. 
I 
77 
Chapter 2: Materials and Method 
4 ASSAYS 
4.1 ASSAY KITS 
a. Adrenomedullin Enzyme Immunoassay 
An adrenomedullin (1-52, human) EIA kit was obtained from Phoenix 
Pharmaceuticals Inc. (Mountain View, CA, USA). The protocol followed was as 
provided with the kit. Data relating to evaluation of the kit was also provided by 
the supplier. No cross-reactivity with other peptides was reported, intra-assay 
error was 5% and inter-assay error was 14 %. 
b. PAMP Enzyme Immunoassay 
A pro-adrenomedullin N-20 (PAMP: human) EIA kit was obtained from Phoenix 
Pharmaceuticals Inc. (California, USA). The protocol followed was as provided 
with the kit. Data relating to evaluation of the kit was also provided by the 
supplier. No cross-reactivity with other peptides was reported, intra-assay error 
was 5% and inter-assay error was 14 %. 
c. Dehydroepiandrosterone (DHEA) Radioimmunoassay 
A DHEA RIA kit was obtained from EuroDPC (Llanberis, UK). The protocol 
followed was as provided with the kit. The data relating to evaluation of the kit 
was also provided by EuroDPC. The antibody provided with the kit did not 
cross-react with other steroids, the intra-assay error was <10.8 % and the inter- 
assay error was <11.7 %. 
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4.2 STEROID MEASUREMENT 
a. Aldosterone Radioimmunoassay 
Aldosterone was measured using an antibody raised in sheep to aldosterone- 
Keyhole Limpet Haemocyanin (KLH). Evaluation of the antibody was as 
previously determined (Cameron, 1994). Intra-assay error (250 fmol/ 100 Al, 
n=20) was 5% and inter-assay error (250 fmol/ 100 µl, n=20) was 11 %. A 
typical standard curve obtained with a working dilution of the antibody can be 
seen in figure 2.3. 
The assay was carried out as follows: 100 µl 3H-aldosterone (10 000 
cpm) in assay buffer (0.15M phosphate buffer, pH 7.4, containing 0.1 % (w/v) 
BSA) was added to appropriate aliquot of standard (50-1 000 fmol/ 100 µl in 
assay buffer) and sample (diluted to 100 µl in assay buffer). 200 pl of antibody 
(freeze-dried aliquots reconstituted to give a working dilution of 1: 24 000) was 
then added to each tube and the tubes mixed thoroughly. The tubes were then 
incubated for 90 minutes at 37°C followed by 60 minutes at 4°C, or overnight at 
4°C. The remainder of the assay was carried out at 4°C. To achieve separation 
of bound and free steroid 200 pl of dextran coated charcoal solution (assay buffer 
containing 0.05 % (w/v) dextran, 0.5 % (w/v) charcoal and 5% (v/v) glycerol) 
was added to each tube. The tubes were mixed thoroughly and incubated at 4°C 
for 10 minutes followed by centrifugation at 10 000 rpm for 5 minutes. 300 µl of 
supernatant was removed to scintilation vials and 1 ml scintilation cocktail 
(Optiphase Highsafe 3) was added. Samples were then counted for 5 minutes 
using a Wallac 1410 liquid scintilation counter. 
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FIGURE 2.3: Typical standard curve obtained with aldosterone RIA. 
n=2, r=0.98 
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b. Cortisol Radioimmunoassay 
Cortisol was measured using an antibody raised in rabbits, against a cortisol-3-(0- 
carboxymethyl)oxime-bovine serum albumin conjugate and obtained from 
BioClin (Cardiff, UK). Cross-reactivity data was provided with the antibody, the 
antibody did not significantly cross-react with other steroids. Intra-assay error 
was 4% and inter-assay error was 9 %. 
The assay method was as follows: 100 µl 1251-cortisol (4 000 cpm) in 
buffer B (0.025 M sodium citrate: dihydrate; 0.05 M sodium dihydrogen ortho 
dihydrate, pH 3.0, containing 0.1 % (w/v) BSA) was added to an appropriate 
aliquot of standard (2.25 - 152 ng/ml) or sample (diluted as necessary in buffer B 
to give final volume 100 µl) and also to tubes T (total counts), NSB (non-specific 
binding) and TB (total binding). Then, 100 µl antibody (resuspended to give 
1: 150 dilution) was added to all tubes with the exception of T and NSB. The 
tubes were thoroughly mixed and incubated overnight at 4°C. On the following 
day, 500 tl of dextran coated charcoal solution (0.05 % (w/v) dextran, 0.5 % 
(w/v) activated charcoal, mixed slowly for 20 minutes at 4°C prior to use) was 
added to each tube except T, and immediately centrifuged at 3 OOOg at 4°C for 15 
minutes. The supernatant was aspirated and the pellets counted for three minutes 
using a LKB-Wallac CliniGamma 1272 gamma counter. 
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4.3 cAMP BINDING PROTEIN ASSAY 
cAMP was measured using an in-house cAMP binding protein assay (Kapas et 
al. 1992). A typical standard curve as obtained with a working dilution of the 
binding protein can be seen in figure 2.4. Inter-assay error (4 pmoll 50 µl, n=20) 
was 6% and inter-assay error (4 pmol/ 50 µl, n=20) was 10 %. 
The entire assay was carried out at 4°C as follows: 50 µl 3H-cAMP (10 
000 cpm) in assay buffer (50 mM tris-HCI, 8 mM theophyline, 6 mM 
mercaptoethanol, pH 7.4) was added to appropriate volume of standard (1-16 
pmol/ 50 µl) and sample (diluted in assay buffer to give a total volume of 50 µl). 
100 pl of binding protein (from frozen aliquots diluted 1: 5 in assay buffer) was 
added to each tube. The tubes were thoroughly mixed and incubated for 90 
minutes. 100 pl of freshly prepared charcoal solution (2 % (w/v) BSA, 10 % 
(w/v) charcoal, in assay buffer mixed slowly for 30 minutes prior to use) was 
added to each tube and the tubes immediately centrifuges at 10 000 rpm for 7 
minutes. 200 pl of supernatant was removed to scintillation vials and 1 ml 
scintillation cocktail (Optiphase Highsafe 3) was added to each vial. The tubes 
were then counted for 5 minutes using a Wallac 1410 liquid scintillation counter. 
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FIGURE 2.4: Typical standard curve as obtained from cAMP binding 
protein assay. n=2, r=0.99. 
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ACTIONS OF PROADRENOMEDULLIN 
N-TERMINAL 20-PEPTIDE (PAMP) IN THE 
RAT ADRENAL CORTEX 
1 INTRODUCTION 
Much has already been determined about the actions of adrenomedullin in the rat 
adrenal cortex. The actions of PAMP, however, a second cleavage product of the 
pre-proAM gene, have been less extensively studied. PAMP has been identified 
in the adrenal glands of several species, including the rat and binding sites for 
PAMP have also been described in the rat adrenal gland (Iwasaki et al. 1996). 
However, as yet specific PAMP binding has not been determined. The aim of 
this study is to determine the effect of PAMP on aldosterone secretion and cAMP 
release from the rat adrenal cortex and also to determine whether specific PAMP 
receptors are present. In addition to this the effect of PAMP on catecholamine 
synthesis was also investigated, because previous studies reporting different 
responsiveness of different tissue preparations have reported that local release of 
catecholamines may be a significant mechanism in the rat zona glomerulosa. 
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2 MATERIALS AND METHODS 
All materials used in this study were as detailed in chapter 2 section 1. All 
methods used were as detailed in chapter 2 section 2 and assays were as detailed 
in chapter 2 section 4. 
Briefly: the effect of PAMP on aldosterone secretion was determined for 
two different tissue preparations, collagenase dispersed zona glomerulosa cells 
and intact capsular tissue. Aldosterone secretion was measured by 
radioimmunoassay. The effect of PAMP on cAMP release was also measured, 
by cAMP binding protein assay, from both tissue preparations. Catecholamine 
release in response to PAMP was measured from intact adrenal capsular tissue 
only. For the binding studies, separated adrenal glands were homogenised to 
give zona glomerulosa and inner zones/medulla cell preparations. Binding data 
was analysed using LIGAND (Munson and Robard 1980). 
Rat PAMP was used in these studies. 
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3 RESULTS 
In collagenase-dispersed zona glomerulosa cells PAMP had very little effect on 
aldosterone secretion (figure 3.1). However, in intact capsular tissue a dose- 
dependent increase in aldosterone secretion in response to PAMP was observed, 
with a minimum significant effect being observed at 1 nmol/l and the maximum 
significant effect at I µmol/l (highest concentration tested; figure 3.2). 
Cyclic AMP release in response to PAMP was also measured in both 
collagenase dispersed zona glomerulosa cells and intact capsular tissue. In 
collagenase dispersed zona glomerulosa cells PAMP caused a dose-dependent 
increase in cAMP release (figure 3.3). The minimum concentration of PAMP 
which had a significant effect was lnmol/l, while the maximum significant effect 
was observed at 100 nmol/l. At this concentration a four-fold increase in cAMP 
release over basal was observed. PAMP also caused a dose-dependent increase 
in cAMP release from intact capsular tissue (figure 3.4). The minimum 
significant effect was observed at a PAMP concentration of I nmol/l. The 
maximum significant effect was observed at a PAMP concentration of 100 
nmol/l, with a two-fold increase over basal. 
The effect of PAMP on aldosterone secretion in the presence of the 
protein kinase A (PKA) inhibitor, HAI 004 (1 µmoVM), was also determined. An 
intact capsule tissue preparation was used as aldosterone response to PAMP had 
been poor in collagenase dispersed zona glomerulosa cells. Aldosterone 
secretion in response to PAMP was significantly decreased in the presence of 
IIA1004 (figure 3.5). ACTH was also tested, as a positive control, and 
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FIGURE 3.1: Aldosterone secretion in response to PAMP from collagenase 
dispersed rat adrenal zona glomerulosa cells. Data are means t 
S. E. M., n=6. *P<0.05 compared to basal values (ANOVA). 
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FIGURE 3.2: Aldosterone secretion in response to PAMP from intact rat 
adrenal capsular tissue. Data are means ± S. E. M., n=6. 
* *P<0.01, ** *P<0.001 compared to basal values (ANOVA). 
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FIGURE 3.3: cAMP release in response to PAMP from collagenase dispersed 
rat adrenal zona glomerulosa cells. Data are means ± S. E. M., 
n=6. **P<0.01, ***P<0.001 compared to basal values (ANOVA). 
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FIGURE 3.4: cAMP release in response to PAMP from intact rat adrenal 
capsular tissue. Data are means ± S. E. M., n=6. *P<0.05, 
**P<0.01, ***P<0.001 compared to basal values (ANOVA). 
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FIGURE 3.5: Aldosterone secretion in response to PAMP (100 nmol/1) and 
ACTH (1 nmol/I) in the absence (open bars) and presence (shaded 
bars) of HA1004 (a PKA inhibitor; 1 pmol/1) from intact rat 
adrenal capsular tissue. Data are means ± S. E. M., n=6. 
** *P<0.001 compared to the response in the absence of HA 1004 
(Student's t-test). 
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FIGURE 3.6: Catecholamine release in response to PAMP (100 nmol/l) from 
intact rat adrenal capsular tissue. Data arc means ± S. E. M., n=6. 
**P<0.01 compared to control levels (ANOVA). 
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aldosterone secretion in response to ACTH was also significantly decreased in 
the presence of HAI 004 (figure 3.5). 
Catecholamine release in response to PAMP was also measured in intact 
rat adrenal capsules. At a concentration of 100 nmol/l PAMP significantly 
decreased catecholamine secretion in rat capsules compared to basal secretion 
(figure 3.6). 
1251-PAMP ligand binding studies were carried out on zona glomerulosa 
cells and inner zone/ medulla cells. 125I-PAMP binding studies in zona 
glomerulosa cells revealed specific saturable binding which indicated the 
presence of two populations of PAMP binding site (figure 3.7). Scatchard 
analysis of zona glomerulosa binding confirmed the presence of two populations 
of binding site (figure 3.8). Both of these sites had similar Kds, Kd1 1.9 nmol/1 
and Kd2 10.0 nmol/l, but had different concentrations of binding site, Bmaxl 53 
fmol/mg protein and B,,, 225 fmol/mg protein. Competition studies were 
carried out with the following peptides, adrenomedullin, CGRP I, CGRP II, 
ACTH, All, amylin and acetylcholine (figure 3.9). Of these compounds, only 
adrenomedullin displaced any of the PAMP binding, Ki>50 nmol/l. None of the 
other compounds tested displaced any of the labelled PAMP. 125I-PAMP binding 
studies in the inner zones/ medulla cells also revealed specific saturable binding 
(figure 3.10). Scatchard analysis of inner zones/ medulla binding revealed a 
single population of binding sites with a Kd of 4.9 nmol/l and a Bmax of 556 
finol/mg protein (figure 3.11). Competition studies were carried out with the 
same compounds as for zona glomerulosa cell competition studies (figure 3.12). 
None of the agents tested, including adrenomedullin, displaced any of the 













100 IL ö 
50 
0 





FIGURE 3.7: Saturation analysis of 125I-PAMP binding in rat adrenal zona 
glomerulosa cells (R), non-specific binding (0). Data are means 
± S. E. M., n=6. 
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FIGURE 3.8: Scatchard plot of 125I"PAMP binding in rat adrenal zona 
glomerulosa cells. Analysis of the plot suggests two populations 
of binding site: Kdl 1.9 nmol/1, Bmax153 fmol/mg protein; Kd2 
10.0 nmol/1, Bmax2 25 finol/mg protein. 
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FIGURE 3.9: Displacement of 1251-PAMP by different competitors in rat adrenal 
zona glomerulosa cells. Specific binding was displaced by PAMP 
and to a lesser extent adrenomedullin. "= PAMP,  = 
adrenomedullin, '= CGRP I, Q= CGRP II, O= ACTH, *= All, 
x= amylin, += acetylcholine. 
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FIGURE 3.10: Saturation curve of 125I-PAMP binding in rat adrenal inner zone/ 
medulla cells (0), non-specific binding (40). Data arc means t 
S. E. M., n=6. 
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FIGURE 3.11: Scatchard plot of 1251-PAMP binding in rat adrenal inner zone/ 
medulla cells. Analysis of the plot suggests a single population of 
binding site: Kd 4.9 nmol/l, B. 556 fmol/mg protein. 
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FIGURE 3.12: Displacement of 125I-PAMP by different competitors in rat adrenal 
inner zone/ medulla cells. Specific binding was displaced only by 
PAMP. "= PAMP,  = adrenomedullin, '= CGRP I, Q= 
CGRP II, Q= ACTH, *= All, x= amylin, += acetylcholine. 
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4 DISCUSSION 
The data presented in this study suggests that in the intact rat adrenal capsule 
PAMP acts to stimulate both aldosterone secretion and cAMP production and 
that in the presence of a PKA inhibitor the effects of PAMP on aldosterone 
secretion were attenuated. It would appear therefore that PAMP acts on the 
intact rat adrenal capsule to stimulate aldosterone secretion via a cAMP- 
dependent mechanism. This is in contrast to the effect observed in collagenase 
dispersed zona glomerulosa cells, where PAMP had little effect on aldosterone 
secretion. However, in collagenase dispersed zona glomerulosa cells PAMP also 
increased cAMP production. This discrepancy may be due to the fact that the cell 
preparations used are not a pure zona glomerulosa cell preparation but also 
contain other cells which would be found in vivo in the adrenal zona 
glomerulosa, such as endothelial cells and chromaffin cells (Gallo-Payet et al. 
1987). It may be that part of the cAMP production from this tissue preparation is 
from cells other than zona glomerulosa cells. As cAMP does not penetrate cells 
very well, cAMP secreted from other cell types would therefore be unavailable to 
zona glomerulosa cells thus explaining why the aldosterone response to PAMP 
was poor in collagenase dispersed zona glomerulosa cells. In particular, 
endothelial cells are abundant in the adrenal. However, as yet no studies have 
measured cAMP release from endothelial cells in response to PAMP, so it 
remains unclear as to whether part of the cAMP release observed is due to the 
actions of PAMP on endothelial cells. While the present study has shown that 
PAMP elevates cAMP release from the rat adrenal, other studies have shown 
PAMP to have no effect on cAMP release. In C6 glioma cells, PAMP did not 
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alter cAMP release while adrenomedullin increased it (Moody et al. 1997). 
Adrenomedullin has been shown to activate two signal transduction pathways in 
bovine aortic endothelial cells, cAMP and Ca2'' signalling (Shimekake et al. 
1995) and it is possible that PAMP may also operate via two signal transduction 
pathways. 
Previous studies have reported that PAMP has no effect on aldosterone 
secretion in dispersed zona glomerulosa cells (Andreis et al. 1997; Neri et al. 
1997). However, these studies also reported that PAMP had an inhibitory effect 
on AII-stimulated aldosterone secretion in dispersed zona glomerulosa cells. 
This discrepancy between the present study and these reported findings could be 
explained by PAMP acting through different receptor subtypes in the rats used in 
the separate studies. Adrenomedullin has also been reported to have different 
effects on aldosterone secretion in different tissue preparations. In intact capsular 
tissue adrenomedullin has been shown to stimulate aldosterone secretion (Kapas 
and Hinson 1996). While in dispersed zona glomerulosa cells adrenomedullin 
has been shown to inhibit aldosterone secretion (Andreis et al. 1997; Neri et al. 
1997). The effects of adrenomedullin are, however, dependent on receptor 
subtype, as adrenomedullin can bind to the CGRP receptor to inhibit aldosterone 
secretion. In the studies with dispersed zona glomerulosa cells the inhibitory 
action of adrenomedullin was blocked by CGRP8_37i a CGRP receptor antagonist 
(Mazzocchi et al. 1996), suggesting that adrenomedullin was acting through the 
CGRP receptor and not through a specific adrenomedullin receptor as was the 
case for intact capsular tissue where adrenomedullin exhibited a stimulatory 
effect (Kapas et al. 1998). As no PAMP receptors have been cloned, to date, it 
is unclear whether PAMP is acting through the same receptor in both studies or 
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if, like adrenomedullin, different subtypes of PAMP receptor are predominant in 
different stains of rat. In this study the effects of PAMP were shown to be 
dependent on the method of tissue preparation used, with PAMP having no effect 
on aldosterone secretion by collagenase digested cells but stimulating aldosterone 
secretion from intact capsular tissue. The effects of other peptides on aldosterone 
secretion are also dependent on the method of tissue preparation used. 
Vasoactive intestinal peptide (VIP) is a peptide whose actions on aldosterone 
secretion are dependent on the tissue preparation method used. Like PAMP, VIP 
stimulates aldosterone secretion from intact capsular tissue but has no effect on 
aldosterone secretion from dispersed zona glomerulosa cells (Hinson et al. 1992). 
All is another peptide whose effects on aldosterone secretion are also dependent 
on the method of tissue preparation used. In contrast to both PAMP and VIP, All 
stimulates aldosterone secretion in dispersed cells but not intact capsular tissue 
(Vinson et al. 1985). This would suggest that part of the signalling mechanism is 
disrupted by cell dispersal as both PAMP and VIP stimulate cAMP release, 
which in a dispersed cell preparation is no longer available to steroidogenic cells, 
while All signals through IP3. It is possible that cell dispersal is somehow 
affecting the PAMP receptor. There are many ways in which this could occur. It 
may be that the mechanism of dispersal is causing the PAMP receptor to be 
degraded, internalised or loose binding specificity for PAMP. This would 
suggest that intraglandular signal transduction mechanisms involving one of the 
other cell type present in the dispersed zona glomerulosa cell population are 
involved in PAMP stimulation of aldosterone secretion. One such possibility is 
local release of catecholamines from chromafin cells (Hinson et al. 1992). 
However this is highly unlikely, as in this study PAMP inhibited release of 
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catecholamines from intact capsular tissue. This finding is consistent with a 
previous study using cultured bovine chromaffin cells which showed a decrease 
in catecholamine secretion in response to PAMP (Katoh et al. 1995; Niina et al. 
1995), the PC 12 cell line (Takano et al. 1996) and human adrenal medullary cells 
(Belloni et al. 1999). 
These data show that PAMP stimulates aldosterone secretion from intact 
rat capsular tissue via a cAMP-dependent mechanism. However, it is possible 
that intraglandular signal transduction mechanisms which are as yet 
uncharacterised are involved in this, because of the discrepancy between tissue 
preparations. 
The data presented in this study has also revealed the presence of specific 
PAMP binding sites within the adrenal gland. A single population of specific 
PAMP binding sites was identified in the inner zones/ medulla tissue. It is likely 
that these receptors are present in the adrenal medulla rather than the zona 
fasciculata or zona reticularis as PAMP production has been identified in the 
medulla (Kuwasako et al. 1995) but not the inner zones of the adrenal cortex. 
Also PAMP has been shown to have no effect on steroid secretion from the inner 
zones of the adrenal cortex but has been shown to inhibit catecholamine synthesis 
and release from the adrenal medulla (Niina et al. 1995; Katoh et al. 1995; 
Belloni et al. 1999). 
1251-PAMP binding in the zona glomerulosa tissue preparation revealed 
two populations of PAMP binding sites. This could be accounted for in several 
ways. As has already been stated the zona glomerulosa cell preparation used 
contains other cell types, such as endothelial and chromaffin cells. It may be that 
the receptor subtype with the lower Bm. is located on one of these other cell 
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types which would be present in the homogenate in lower numbers, thus 
explaining its lower number of binding sites. Alternatively these could be two 
populations of PAMP receptor, one with a higher affinity and lower receptor 
number and one with a slightly lower affinity but greater cell number. However, 
when considered in conjunction with the competitor studies which showed that 
adrenomedullin displaced labelled PAMP it would appear that these are two 
separate receptors, one of which is a specific PAMP receptor and the other which 
also binds adrenomedullin. Of the adrenomedullin receptors characterised to 
date, none are known to bind PAMP. As no PAMP receptors have been cloned 
to date it is therefore unclear as to how many types of PAMP receptors exist. 
However, data presented in this study would suggest that at least two PAMP 
receptors exist, one which does not bind adrenomedullin and one which does, 
exist. It is of note that PAMP and adrenomedullin acting as ligands for the same 
binding site would seem unlikely as they share no structural homology. One 
possible theory is that while PAMP and adrenomedullin are ligands for the same 
receptor they do not share the same binding site. The receptor may have two 
binding sites, one for PAMP and one for adrenomedullin. Binding of one of 
these peptides may cause a conformational change in the receptor thus preventing 
the other from binding and activating the receptor. Therefore it may be that one 
of these peptides may act as a non-competitive antagonist for the other. At 
present there is no evidence to support it this theory. 
The three dissociation constants found in the present study are in a similar 
range, 1.9-10.0 nmol/l. These show higher affinity than the PAMP receptor 
previously reported in vascular smooth muscle cells, which had a Kd of 35 nmol/l 
(Iwasaki et al. 1996). This would suggest that PAMP receptors in the adrenal 
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gland are not activated by circulating PAMP which is in the low pmol range 
(Washimine et al. 1994), but most probably by locally produced PAMP. PAMP 
has been shown to be produced in the adrenal gland, in both the zona 
glomerulosa cells and the medulla (Kuwasako et al. 1995), suggesting that 
PAMP may have an autocrine, as well as paracrine role in adrenal function. 
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CHAPTER 4 
PRODUCTION AND ACTION 
OF ADRENOMEDULLIN AND PAMP 
IN THE H295R CELL LINE 
1 INTRODUCTION 
Adrenomedullin and PAMP are hypotensive peptides which are cleavage 
products of the same gene. They were first identified in pheochromocytoma 
extracts but more recently adrenomedullin has been identified in the adrenal 
cortex. There is evidence that both of these peptides have an effect on steroid 
secretion by the rat and human adrenal gland, although the exact effect is unclear. 
To date, two candidate adrenomedullin receptors have been identified, LI and 
CRLR/RAMP-2, but as yet no PAMP receptor has been identified. The aim of 
this study is to establish whether the genes encoding adrenomedullin, PAMP and 
the two candidate adrenomedullin receptors, L1 and CRLR/RAMP-2, are 
expressed by H295R cells and also to determine the effect of adrenomedullin and 
PAMP on steroid secretion. 
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2 MATERIALS AND METHODS 
All materials used were as stated in chapter 2, section 1. Methods used were as 
stated in Chapter 2, section 3 and steroid, peptide and cAMP assays used were as 
stated in Chapter 2 section 4. 
Briefly, immunocytochemistry was carried out to determine whether 
adrenomedullin and PAMP were present in the H295R cell line. In addition to 
this PCR was also carried out for adrenomedullin and PAMP, both before and 
after treatment with angiotensin II and forskolin as well as adrenomedullin and 
PAMP. Enzyme immunoassay for adrenomedullin and PAMP was used to 
determine the level of secretion of these two peptides by H295R cells. 
Radioimmunoassay for aldosterone, cortisol and DHEA was carried out 
on cell culture medium from cell which had been incubated with adrenomedullin 
or PAMP. Cells were also pre-treated with angiotensin II and forskolin then 
treated with adrenomedullin and PAMP to determine the possible zonal effects of 
these two peptides on steroid secretion from the adrenal gland. 
Finally, immunocytochemistry was carried out to determine if the two 
candidate adrenomedullin receptors L1 and CRLR are present in H295R cells. 
PCR was also carried out for L1 and CRLR as well as the two CRLR accessory 
proteins RAMPs -1 and -2. 
Human adrenomedullin and PAMP were used in these studies. 
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3 RESULTS 
3.1 Production of Adrenomedullin and PAMP 
To determine whether adrenomedullin and PAMP are produced by H295R cells 
immunocytochemistry was carried out using specific antibodies to both peptides. 
Specific staining for adrenomedullin is shown in figure 4.1a. Intense staining 
was seen throughout the cytoplasm and although the nuclei of the positively 
stained cells appeared darker than those of the control cells this could be 
attributed to staining of the overlying cytoplasm and not necessarily indicative of 
nuclear staining. Figure 4.1b shows non-specific binding of adrenomedullin, the 
antibody had been pre-absorbed with adrenomedullin antigen. As can be seen 
from figure 4.2a PAMP was also produced by H295R cells. Staining in these 
cells was not so uniform throughout the cytoplasm, tending to be concentrated 
around the nucleus and extending into the cytoplasm on only one side of it. As 
with adrenomedullin staining (figure 4.1a) darker staining of the nucleus may be 
due to overlying cytoplasm. 
PCR analysis using primers for pre-proadrenomedullin exon 4 sense and 
antisense (adrenomedullin) and exon 2 sense and exon 3 antisense (DAMP; 
figures 4.3 and 4.4 respectively) show bands corresponding to adrenomedullin 
and PAMP in H295R cDNA. H295R cDNA from cells which had been pre- 
treated for 48 hours with either All (10 nmol/1) or forskolin (10 µmol/1) was also 
subjected to PCR for adrenomedullin and PAMP (figures 4.3 and 4.4 
respectively). Pre-treatment with forskolin did not appear to affect 
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FIGURE 4.1: Immunocytochemistry for a) adrenomedullin antibody and b) 
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adrenomedullin expression as the band was of approximately the same intensity 
as that of untreated H295R cDNA, while the band amplified from cDNA from 
All pre-treated cells was more intense (figure 4.3). The reverse of this would 
appear to be true for PAMP (figure 4.4) as the band amplified in the forskolin 
pre-treated sample appeared to be more intense than either of the bands from the 
no pre-treatment or All pre-treated samples, both of which were approximately 
the same intensity. Interestingly, PCR analysis for adrenomedullin and PAMP, in 
cDNA from H295R cells which had previously been treated with either 
adrenomedullin or PAMP, show that mRNA for either peptide was not present 
(figure 4.3 and 4.4). It should however be noted that this is not a quantitative 
method and these are merely observations. Attempts to amplify the full pre- 
proadrenomedullin sequence in both H295R cDNA and human adrenal cDNA 
were unsuccessful (data not shown). 
The amount of adrenomedullin and PAMP being secreted by H295R cells 
was determined by enzyme immunoassay. Adrenomedullin secretion was 
significantly increased, over basal secretion, in the presence of All (figure 4.5). 
There was also a significant increase in adrenomedullin secretion in the presence 
of forskolin although this was not as great as the increase observed in response to 
All (figure 4.5). Secretion of PAMP was also significantly increased in the 
presence of both All and forskolin, although a much greater increase was 
observed in the presence of forskolin (figure 4.6). In neither of the above cases 
was the increase in peptide secretion enhanced by daily medium replacement, as 
no increase was observed in control medium compared to basal. Adrenomedullin 
and PAMP secretion per well is shown in figure 4.7. The trendline in figure 4.7a 
represents equimolar quantities of adrenomedullin and PAMP. As can be seen in 
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this figure adrenomedullin was secreted in greater quantities than PAMP in all 
cases. There was however, no clear relationship between adrenomedullin and 
PAMP secretion. These data taken together with the fact that PCR between 
exons 3 and 4 of the pre-proAM gene was unsuccessful in cDNA but not 
genomic DNA (data not shown), suggest that expression of adrenomedullin and 
PAMP may be regulated at the transcriptional level, at least in this cell type. 
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FIGURE 4.5: Adrenomedullin secretion by H295R cells. Cells were treated with 
All (10 nmol/1) or forskolin (10 µmol/1) for 48 hours. Data are 

















FIGURE 4.6: PAMP secretion by H295R cells. Cells were treated with All (10 
nmol/1) or forskolin (10 µmo1Jl) for 48 hours. Data are means ± 
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FIGURE 4.7: Adrenomedullin and PAMP secretion per well, where Q= basal, 
0= control, A= All-treated (10 nmol/1) and x= forskolin-treated 
(10 µmol/I) for 48 hours a) each point represents individual wells, 
trendline r=1 represents equimolar quantities of adrenomedullin 
and PAMP b) mean ± S. E. M., n=5. 
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3.2 Action of Adrenomedullin and PAMP 
a. Actions on Steroidogenesis 
Both adrenomedullin and PAMP caused a dose-dependent increase in 
aldosterone secretion from H295R cells (figure 4.8a and b). In both cases the 
minimum concentration of pcptide required for a significant increase was 
1 nmol/l. The maximum increase observed was at a peptide concentration of 
100nmol/1 for either peptide. At this concentration a 4-fold increase over basal 
was observed in aldosterone secretion in response to adrenomedullin and PAMP. 
There was no increase in aldosterone secretion in response to CGRP (figure 
4.8c). 
Both adrenomedullin and PAMP also caused a dose-dependent increase 
in cortisol secretion from H295R cells (figure 4.9a and b). The minimum 
significant increase in cortisol secretion was observed at l00pmolA and the 
maximum increase at I00nmol/l, in response to either peptides. At 100nmol/l a 
14-fold increase in cortisol secretion over basal was observed in adrenomedullin 
and PAMP. Again no response in steroid secretion was observed in response to 
CGRP (figure 4.9c). 
PAMP also caused a dose-dependent increase in DHEA secretion (figure 
4.10b). The minimum concentration of PAMP required for a significant increase 
was lOpmol/1 (the minimum concentration tested) however, this is most likely 
due to the very low basal level of DHEA secretion. The maximum effect of 
PAMP was at 100nmoV1, which was a 7"fold increase over basal. Neither 































FIGURE 4.8: Aldosterone secretion in response to a) adrenomedullin b) PAMP 
and c) CGRP. Data are means ± S. E. M., n=4. **P<0.01, 
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FIGURE 4.9: Cortisol secretion in response to a) adrenomedullin b) PAMP and 
c) CGRP. Data are means ± S. E. M., n=12. **P<0.01, 
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FIGURE 4.9: continued. 
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FIGURE 4.10: DHEA secretion in response to a) adrenomedullin b) PAMP and 
c) CGRP. Data are means ± S. E. M., n=4. **P<0.01, ***P<0.001 
compared to basal values (ANOVA). 
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FIGURE 4.10: continued. 
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Treatment of H295R cells with adrenomedullin and PAMP for 48 hours 
gave rise to a similar increase in aldosterone secretion as was observed with 48 
hour All treatment (figure 4.11). No significant increase in aldosterone secretion 
was observed with either CGRP or forskolin pre-treatment. Pre-treatment with 
both adrenomedullin and PAMP also cause a significant increase in cortisol 
secretion, as did forskolin pre-treatment (figure 4.12). No significant increase 
was observed after All or CGRP pre-treatment. DHEA secretion was not 
affected by pre-treatment with either adrenomedullin, CGRP or All (figure 4.13). 
PAMP however, did cause a significant increase in DHEA secretion, although 
this was not as great as the increase observed after forskolin pre-treatment. 
The effect of adrenomedullin and PAMP on steroid secretion was also 
determined in cells which had been pre-treated with either All or forskolin and 
compared with cells which had not received pre-treatment. Both adrenomedullin 
and PAMP gave rise to a 4.5-fold increase in aldosterone secretion with no pre- 
treatment, which was similar to the increase observed with All (figure 4.14a). A 
2-fold increase in aldosterone secretion was observed in the presence of forskolin 
(figure 4.14a). After pre-treatment with All, aldosterone in the control sample 
had increased 6-fold over basal aldosterone secretion. Both adrenomedullin and 
PAMP caused an increase, 2-fold and 1.5-fold respectively, in aldosterone 
secretion in AII pre-treated cells (figure 4.14b). Additional All, after All pre- 
treatment, did not give rise to a further increase in aldosterone secretion (figure 




























FIGURE 4.11: Aldosterone secretion after 48 hour treatment with adrenomedullin 
(100 nmol/1), PAMP (100nmol/1) and CGRP (100 nmol/1) 
compared with All (10 nmoUl) and forskolin (10 µmol/1). Data 
are means ± S. E. M. n=4. **P<0.01 compared to basal values 
(Student's t-test). 
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FIGURE 4.12: Cortisol secretion after 48 hour pre-treatment with adrenomedullin 
(100nmo1/1), PAMP (100 nmol/1) and CGRP (100 nmol/1) 
compared with All (10 nmol/1) and forskolin (10 pmol/1). Data 
are means ± S. E. M. n=4. **P<0.01 compared to basal values 
(Student's t-test). 
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FIGURE 4.13: DHEA secretion after 48 hour pre-treatment with adrenomedullin 
(100 nmol/1), PAMP (100 nmol/l) and CGRP (100 nmol/1) 
compared with All (10 nmol/1) and forskolin (10 pmol/l). Data 
are means ± S. E. M. n=4. **P<0.01 compared to basal values 
(Student's t-test). 
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aldosterone secretion compared with All pre-treatment control, however this 
decrease was not significant (figure 4.14b). Pre-treatment with forskolin gave 
rise to a 2-fold increase in aldosterone secretion over basal levels. The increase 
observed after 48 hour pre-treatment was not significantly altered from the 
increase observed after 4 hours. Additional forskolin, after the 48 hour pre- 
treatment, had no further effect on aldosterone secretion (figure 4.14a and c). 
Adrenomedullin significantly increased aldosterone secretion in forskolin pre- 
treated cells, causing a 2-fold increase over forskolin pre-treated control levels 
(figure 4.14c). PAMP however, had no effect on aldosterone secretion in 
forskolin pre-treated cells (figure 4.14c). All also significantly increased 
aldosterone secretion in forskolin pre-treated cells (figure 4.14c). 
In cells which had not been pre-treated, cortisol secretion was increased 
4-fold and 3.7-fold, respectively, in response to adrenomedullin and PAMP 
(figure 4.15a). Forskolin gave rise to a 4.5-fold increase in cortisol secretion 
(figure 4.15a). All had no effect on cortisol secretion. Pre-treatment with All 
had no effect on cortisol secretion (figure 4.15b). Both adrenomedullin and 
PAMP caused a 3.3-fold increase in cortisol secretion in All pre-treated cells, 
compared to a 4-fold increased observed in response to forskolin (figure 4.15b). 
Pre-treatment with forskolin significantly increases cortisol secretion, 2.3-fold 
compared with no pre-treatment control levels. However, this is significantly 
lower than cortisol secretion in response to forskolin after 4 hours, which was 
4.5-fold greater than no pre-treatment control levels. Additional forskolin, after 
48 hour forskolin pre-treatment, gave rise to a significant increase in cortisol 
secretion, 2-fold compared with forskolin pre-treatment control values, the 
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concentration of cortisol observed after this was similar to that observed after 4 
hours (figure 4.15 a and c). 
Neither adrenomedullin nor All had any effect on DHEA secretion 
(figure 4.16a). A 10-fold increase in DHEA secretion was observed in the 
presence of PAMP (figure 4.16a). Forskolin also significantly increased DHEA 
secretion (figure 4.16a). Pre-treatment with All did not affect DHEA secretion 
(figure 4.16b). Both PAMP and forskolin, but not adrenomedullin, caused a 
significant increase in DHEA secretion in All pre-treated cells (figure 4.16b). 
Forskolin pre-treatment greatly increased DHEA secretion compared to no pre- 
treatment (figure 4.16a and c). Neither adrenomedullin nor All had any affect on 
DHEA secretion in forskolin pre-treated cells (figure 4.16c). PAMP however did 
cause a significant increase in DHEA secretion in forskolin pre-treated cells 
compared with forskolin pre-treated control levels (figure 4.16c). Additional 
forskolin did not affect DHEA secretion after pre-treatment however, DHEA 
secretion in response to forskolin was increased 4.4-fold after 48 hours over 4 
hours (figure 4.16a and c). 
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FIGURE 4.14: Aldosterone secretion in response to adrenomedullin (I00nmol/1) 
and PAMP (100nmol/1), compared with no agonist (control), All 
(10nmo1/1) and forskolin (lOpmol/1) in H295R cells which had 
received a) no pre-treatment b) All pre-treatment or c) forskolin 
pre-treatment. Cells were incubated for 4 hours after 48 hour pre- 
treatment. Data are mean ± S. E. M., n=4. *P<0.05, ***P<0.001 
compared to control values (Student's t-test). 
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FIGURE 4.15: Cortisol secretion in response to adrenomedullin (I00nmol/1) and 
PAMP (100nmo1/1), compared with no agonist (control), All 
(lOnmol/1) and forskolin (10µmol/1) in H295R cells which had 
received a) no pre-treatment b) All pre-treatment or c) forskolin 
pre-treatment. Cells were incubated for 4 hours after 48 hour pre- 
treatment. Data are mean ± S. E. M., n=4. *P<0.05, ***P<0.001 
compared to control values (Student's t-test). 
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FIGURE 4.16: DHEA secretion in response to adrenomedullin (I00nmol/1) and 
PAMP (100nmol/1), compared with no agonist (control), All 
(10nmol/1) and forskolin (lOµmol/1) in H295R cells which had 
received a) no pre-treatment b) All pre-treatment or c) forskolin 
pre-treatment. Cells were incubated for 4 hours after 48 hour pre- 
treatment. Data are mean ± S. E. M., n=4. *P<0.05, ***P<0.001 
compared to control values (Student's t-test). 
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b. Actions on Enzyme Regulation 
PCR analysis of three steroidogenic enzymes, 30-hydroxysteroid dehydrodgenase 
(3ß-HSD), CYP17 and CYP11B2, was carried out on cDNA from H295R cells 
which had been treated with either adrenomedullin (100 nmol/l), PAMP 
(100nmol/l), All (10 nmol/1) or forskolin (10 pmol/1) or had received no pre- 
treatment (figure 4.17a, b and c). In general, pre-treatment did not appear to 
effect expression of steroidogenic enzymes as bands of similar intensity were 
present in each lane, although again this is not a quantitative method and these 
are merely observations. The intensity of the band representing 3ß-HSD in both 
All and forskolin pre-treated cells appeared to be less intense than that of 
untreated H295R cDNA (figure 4.17a). Likewise, the band representing CYP17 
in All pre-treated cells appeared fainter than the band from cells which had 
received no pre-treatment (figure 4.17b). 
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c. Second Messengers 
A dose-dependent increase in cAMP release was observed in response to both 
adrenomedullin and PAMP (figure 4.18a and b). The minimum concentration of 
adrenomedullin required for a significant increase in cAMP release was 
100pmol/l, with 100nmol/1 giving the maximum increase, a 4-fold increase over 
basal. The maximum increase observed in cAMP release in response to 
adrenomedullin was significantly lower than cAMP release in response to 
forskolin (figure 4.18a). The minimum concentration at which PAMP caused a 
significant increase in cAMP release was I nmolIl, the maximum increase was at 
100nmoUl. At this concentration an 8-fold increase was observed. 
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FIGURE 4.18: CAMP release in response to a) adrenomedullin and b) PAMP. 
Data are means ± S. E. M., n=3. *P<0.05, *** P<0.001 compared 
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3.3 Adrenomedullin Receptors 
Immunocytochemistry for the candidate adrenomedullin receptor, L1, revealed 
that it is present in H295R cells (figure 4.19). The presence of mRNA was 
confirmed by PCR (figure 4.20). Pre-treatment of H295R cells for 48 hours with 
adrenomedullin (100nmol/1), PAMP (100nmol/1), All (10 nmol/1) or forskolin (10 
pmoVl) did not appear to affect L1 receptor expression, as bands corresponding 
to L1 are visible in each lane. 
The other candidate adrenomedullin receptor, CRLR, was also revealed to 
be expressed by in H295R cells by immunocytochemistry (figure 4.21). Again 
the presence of the mRNA was confirmed by PCR (figure 4.22a). Treatment of 
the cells for 48 hours with adrenomedullin (100 nmol/1) or All (10 nmol/1) did 
not alter the intensity of band amplified. However, treatment with forskolin (10 
µmol/1) reduced receptor expression as only a very faint band can be seen in the 
corresponding lane. Treatment with PAMP (100 nmol/I) would appear to knock 
out receptor expression altogether, as no band can be seen in the corresponding 
lane (figure 4.22a). Expression of both RAMP-1 and RAMP-2, the proteins 
which complex with CRLR to confer either CGRP or adrenomedullin specificity 
respectively, was also analysed by PCR (figure 4.22b and c). RAMP-2 was 
found to be expressed in H295R cells and pre-treatment with adrenomedullin, 
All or forskolin did not have any effect on the amplified band. However, pre- 
treatment with PAMP would appear to reduce expression of RAMP-2, as the 
band in the corresponding lane is barely visible (figure 4.22c). RAMP-1 was not 
found to be expressed in H295R cells under any condition, but was amplified 
from human adrenal cDNA (figure 4.22b). 
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FIGURE 4.19: Immunocytochemistry showing staining for a) L1 antibody and b) 
L1 antibody pre-absorbed with L1 antigen. 
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FIGURE 4.21: Immunocytochemistry showing staining for a) CRLR antibody 
and b) CRLR antibody pre-absorbed with CRLR antigen. 
147 

('hupter 4: Production und i1 rtion cf Adrenome(hnllin and i'AAIi' in the l i2')SK ('eil Line 
I 
Q```ýý ýOJ P 
805 hp * 







FIGURE 4.22: PCR analysis of a) CRLR h) RAMP-I and c) RAMP-2 in cl)NA 
from treated and untreated 11295R cells. 
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4 DISCUSSION 
a. H295R Cells 
This study used the relatively new tool of the H295R adrenocortical cell line. An 
important factor in the determination of the results presented in this study is if the 
H295R cells were responding to stimuli as had previously been reported. When 
these cells were first characterised they were reported to secrete, under basal 
conditions, the major adrenocortical steroids (Gazdar et al. 1990). Subsequent 
studies using these cells have reported that aldosterone secretion is increased in 
response to All (Bird et al. 1993; Holland et al. 1993). Aldosterone secretion is 
also increased in response to forskolin, although the effect is not as great as that 
observed with All (Holland et al. 1993). In the present study aldosterone 
secretion was significantly increased by All and forskolin, with All having the 
greater effect, in good agreement with the published literature (Bird et al. 1993; 
Holland et al. 1993). Previous studies also report that cortisol secretion is 
increased in the presence of forskolin and dbcAMP (Rainey et al. 1993) and that 
after 24 hours of forskolin treatment cortisol becomes the major secretory 
product of the H295R cell line (Rainey et al. 1994). This is certainly the case in 
the present study, where cortisol secretion was greatly increased with forskolin 
and after 48 hours of pre-treatment cortisol was the major secretory product. As 
for DHEA secretion, it has previously been reported that it is greatly increased by 
forskolin but not altered by All (Bird et al. 1996; Rainey et al. 1994). These 
were also the effects on DHEA secretion reported in the present study. As for 
expression of steroidogenic enzymes, it has previously been reported that All 
increases expression of CYP11B2, CYP17 and 3 ß-HSD (Bird et al. 1996; Bird et 
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al. 1998) and that forskolin increases CYP17 and 3ß-HSD expression although 
the increase in CYP17 expression is greater (Bird et al. 1996). The results 
obtained from PCR of CYP 11 B2, CYP17 and 3 ß-HSD in the present study 
would tend to support this, with forskolin appearing to increase expression of 
17a-hydroxylase and angiotensin II increasing expression of aldosterone 
synthase. 3ß-HSD expression was however, not altered by treatment with any of 
the agonists tested. 
It therefore appears that the H295R cell line was behaving as expected, 
with All causing the cells to display zona glomerulosa characteristics, while 
forskolin produced a zona fasciculata/reticularis type cell, although the 
conversion was not complete because aldosterone was still secreted, albeit in very 
small amounts, after forskolin pre-treatment. 
b. Adrenomedullin and PAMP Expression in H295R Cells 
Data presented in this study show that the gene encoding both adrenomedullin 
and PAMP is expressed by H295R cells, and that both peptides are present within 
the adrenocortical cells, and secreted into the medium. This is consistent with 
other cell lines which have also been shown to express the adrenomedullin gene 
and to secrete adrenomedullin peptide (Miller et al. 1996). These findings are 
also consistent with previous reports of adrenomedullin gene expression in the rat 
adrenal gland (Kapas et al. 1998) and in cultured human adrenocortical cells (Liu 
et al. 1997). Adrenomedullin peptide has also been identified in the rat zona 
glomerulosa (Kapas et al. 1998) and in the human SW13 adrenocortical cell line 
(Takahashi et al. 1998). The increase observed in both adrenomedullin and 
PAMP secretion after pre-treatment with All, which produces the zona 
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glomerulosa phenotype, is consistent with previous studies which have shown the 
adrenomedullin gene to be expressed in the zona glomerulosa of the adrenal 
cortex (Kapas et al. 1998). 
c. Regulation of Adrenomedullin 
Adrenomedullin secretion was increased in the presence of both All and 
forskolin, while adrenomedullin gene expression is only increased by All. 
Previous studies have generally shown adrenomedullin secretion to be inhibited 
by activators of cAMP and stimulated by activators of IP3/protein kinase C 
(Hattori et al. 1999; Lai et al. 1998), so it might be expected that All would 
stimulate adenomedullin while forskolin would inhibit secretion. Other than the 
study by Isumi et al. (1998), which showed no effect of angiotensin II on 
adrenomedullin, the effect of these two peptides has not been directly 
investigated. Studies using human macrophages found that the phorbol ester, 
TPA, which activates protein kinase C, also stimulates adrenomedullin gene 
transcription and secretion (Kubo et al. 1998). 
In the present study, forskolin, a direct activator of adenylate cyclase, 
caused an increase in adrenomedullin secretion into the culture medium, but did 
not alter adrenomedullin gene expression. Previous studies investigating the 
effects of forskolin have produced conflicting results, depending at least partly on 
the cell type used in the study. In rat endothelial cells adrenomedullin secretion 
was not affected by forskolin (Isumi et al. 1998). Forskolin was also without 
effect on transcription of adrenomedullin in messangial cells but did down- 
regulate transcription in glomerular epithelial cells (Li et al. 1998). One previous 
study has also reported an increase in adrenomedullin secretion in response to a 
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cAMP analogue, although in this study there was a decrease in adrenomedullin 
transcription in cultured adrenal bovine chromaflin cells in response to the cAMP 
analogue, dbcAMP (Kobayashi et al. 1999). These reported findings, taken 
together with the results from the present study suggest that there may be cell 
specific mechanisms involved in the regulation of adrenomedullin. Interestingly, 
the study carried out by Isumi et al. (1998) in rat endothelial cells, in addition to 
reporting no effect of forskolin on adrenomedullin secretion, also reported no 
effect of angiotensin II on adrenomedullin secretion. They did however show a 
significant increase in adrenomedullin secretion in response to both aldosterone 
and cortisol. It is thus possible that part of the increase observed in 
adrenomedullin secretion in the present study could be contributed via these 
actions of angiotensin II and forskolin on steroid secretion. There are two 
different ways in which it may be possible to determine whether the actions of 
angiotensin II and forskolin are dependent on the increased steroid production: 
first by using an inhibitor of steroidogenesis, such as aminoglutethimide, an 
inhibitor of cholesterol side chain cleavage, and second by using specific receptor 
antagonists, spironolactone for aldosterone and RU486 for cortisol. 
d. Regulation of PAMP 
Like adrenomedullin, PAMP secretion was also increased after both All and 
forskolin pre-treatment. However, contrary to the increases observed with 
adrenomedullin secretion, PAMP secretion was increased to a greater extent by 
forskolin pre-treatment than by All pre-treatment. This may suggest that PAMP 
could be present in the inner zones of the adrenal cortex although to date this has 
not been investigated. However, the adrenomedullin gene does not appear to be 
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expressed in the inner zones of the rat adrenal cortex (Kapas ct a!. 1998). The 
study by Kobayashi et al. (1999) also reported that PAMP secretion was 
increased in the presence of the cAMP analogue, dbcAMP. This would support 
findings in the present study which showed an increase in PAMP secretion in 
response to forskolin. However, the data presented in this study would suggest 
that transcription of the region of the adrenomedullin gene encoding PAMP is 
also increased in response to forskolin and this is contrary to the study by 
Kobayashi et a!. (1999) who reported a decrease in PAMP transcription in 
response to dbcAMP. 
It would therefore appear that both adrenomedullin and PAMP are not 
constitutively expressed but are actively regulated. It is however also of interest 
that immunoreactive (ir)-adrenomedullin and ir-PAMP measured in the culture 
medium were not equimolar and that the ratio of adrenomedullin to PAMP was 
not constant with pre-treatment, the greatest difference being observed after 
forskolin pre-treatment. No storage granules for adrenomedullin have been 
located within cells and it is thought that this peptide is not stored but is 
constitutively secreted (Takahashi et a!. 1998; Isumi et al. 1998). Therefore it 
would appear that this altered ratio of adrenomedullin to PAMP, observed after 
different pre-treatments, is a result of increased expression and not an increase in 
release of stored peptide. Although the differences in the ratio of ir- 
adrenomedullin to ir-PAMP could be accounted for differences in rates of 
degradation of both peptides this would be unlikely to account for the altered 
ratios after pre-treatment. Other studies (Kobayashi et a!. 1999) have also shown 
that ir-adrenomedullin and ir-PAMP are not equimolar in cultured bovine adrenal 
chromaffin cells, although, to date, this has not been directly looked at. Other 
154 
a, °roa uc 10 ORp/9 Plf_OI1lA r! M ! the 112931 
peptides which are cleavage products of the same gene, for example the products 
of POMC, are expressed in a ratio close to one to one, even after glucocorticoid 
treatment at concentrations which inhibit synthesis of precursor 2- to 3-fold 
(Herbert et al. 1980). This however, is not the case for adrenomedullin and 
PAMP. In the present study adrenomedullin is secreted in greater quantities than 
PAMP in all pre-treatments. This is consistent with the reported findings of 
Kobayashi et al. (1999), who also found that adrenomedullin was secreted in 
greater quantities than PAMP. Furthermore, the ratio of PAMP to 
adrenomedullin does not remain constant and is altered depending on culture 
conditions. These results would suggest that the expression of these two peptides 
may be independently regulated and that the level of transcriptional regulation 
involved in expression of adrenomedullin and PAMP is greater than has so far 
been elucidated. To date, little is known about the transcriptional regulation of 
adrenomedullin and PAMP. While the entire pre-proAM gene has been shown to 
be transcribed (Lai et al. 1998) attempts in the present study to amplify pre- 
proAM were unsuccessful. While this could be due to a technical issue it may 
also be one of two other reasons. It may be that pre-proAM is very transient, 
being translated or degraded very quickly, or that under certain conditions, or in 
different tissues, adrenomedullin and PAMP are independently and differentially 
regulated. The regulation of adrenomedullin and PAMP is an area which would 
warrant further study. While the data available on the subject would suggest that 
adrenomedullin and PAMP may be differentially regulated it is by no means clear 
or conclusive. 
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e. PCR 
In the present study, the method of rt-PCR used was not quantitative. Intensity of 
bands obtained from rt-PCR analysis were compared to the intensity of bands 
obtained from rt-PCR for GAPDH, which remained constant after treatment. 
Therefore the results obtained from rt-PCR are observations only. However, the 
PCR data presented are typical observations from experiments which have been 
repeated at least three times, using fresh cell preparations each time. Each PCR 
was then repeated at least three times. In every case the results were remarkably 
reproducible. Despite the lack of formal quantification, it is felt that these are 
reliable observations. 
It would have been advantageous to carry out a quantitative method to 
determine the level of transcript of the pre-proAM gene present in these cells, 
and indeed all other genes amplified, such as competitive PCR or northern blot 
analysis. Both of these methods however, require a large quantity of RNA and as 
H295R cells grow quite slowly it was not practical to culture enough of the 
H295R cells to yield enough RNA to carry out one of these more quantitative 
method of mRNA analysis. Based on the PCR data presented in this study it 
would be beneficial to conduct further, quantitative methods of mRNA analysis 
to certain of the transcripts for which PCR analysis was carried out for. 
f. Are Adrenomedullin and PAMP Self Regulating? 
Data presented in this study would suggest that both adrenomedullin and PAMP 
are self-regulating, as pre-treatment of these cells with adrenomedullin or PAMP 
effectively knocked-out gene expression of both peptides. It has previously been 
shown that adrenomedullin and PAMP synthesis is regulated in part by at least 
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one cAMP dependent pathway in adrenal chromaffin cells (Kobayashi et al. 
1999). This study reported that the cAMP analogue dbcAMP, inhibited 
adrenomedullin and PAMP synthesis. While the data obtained from pre- 
treatment with adrenomedullin and PAMP would support this, the data obtained 
from forskolin pre-treatment would not. Despite the concentrations of 
adrenomedullin, PAMP and forskolin used stimulating cAMP release to 
approximately the same degree, pre-treatment with forskolin did not appear to 
have any affect on adrenomedullin expression. However, expression of PAMP 
appeared to be increased in the presence of forskolin. This would suggest that 
while adrenomedullin and PAMP do appear to be self-regulating there is more 
than cAMP involved, as forskolin does not appear to have this effect. 
Adrenomedullin has been shown to operate via two signalling pathways in 
bovine aortic endothelial cells, cAMP accumulation and Ca2+ mobilisation 
(Shimekake et al. 1995). It is possible that Ca2+ is involved in the regulation of 
adrenomedullin gene expression. This could be further tested by treating the 
cells with Ca2+ channel blockers and stimulators and measuring expression of the 
adrenomedullin gene. 
g. Steroid Production 
i. Effects on Aldosterone Secretion 
Both adrenomedullin and PAMP have previously been shown to be regulators of 
aldosterone secretion. There have however, been contradictory reports on the 
effects of both of these peptides on aldosterone secretion. Both adrenomedullin 
and PAMP have been shown to inhibit aldosterone secretion in rat and human. 
Studies using collagenase-dispersed rat and human adrenal zona glomerulosa 
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cells demonstrated an inhibitory effect of adrenomedullin on All-stimulated 
aldosterone secretion (Andreis et al. 1997a; Andreis et al. 1997b; Andreis et al. 
1998). This effect was however mimicked by CGRP and reversed by the CGRP 
receptor antagonist, CGRP8.37, suggesting that adrenomedullin was acting 
through the CGRP receptor and that this effect was not mediated by a specific 
adrenomedullin receptor. Other studies have reported a stimulatory effect of 
adrenomedullin on aldosterone secretion in the rat adrenal cortex (Kapas et a!. 
1998; Hinson et al. 1998) and in human adrenal slices when acting through 
specific adrenomedullin receptors (Andreis et al. 1997a). The data presented in 
this study on H295R cells is consistent with findings that adrenomedullin has a 
stimulatory effect on aldosterone secretion. This suggests that in this cell line 
adrenomedullin is acting through specific adrenomedullin receptors and not 
through the CGRP receptor. Also CGRP had no effect on aldosterone secretion 
in this cell line, suggesting that the CGRP receptor may not be present in the 
H295R cell line. Not only did adrenomedullin cause a dose-dependent increase 
in basal secretion of aldosterone, but also a time-dependent increase, the levels of 
aldosterone after 48 hours were 2-fold greater than after 4 hours. This 
stimulatory action of adrenomedullin was also observed after 48 hour pre- 
treatment with both All and forskolin, although basal aldosterone secretion was 
not altered by pre-treatment with forskolin. This would suggest that in this cell 
line the stimulatory actions of All and adrenomedullin are independent of each 
other. PAMP has also been reported to have an inhibitory effect on All- 
stimulated aldosterone secretion in rat and human collagenase-dispersed zona 
glomerulosa cells and basal aldosterone secretion in Conn's adenoma cells 
(Andreis et al. 1997b; Andreis et al. 1998). These effects of PAMP however, 
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were not reversed by CGRPs. 37, suggesting that it was acting through a specific 
receptor and that its mechanism of action was different to that of adrenomedullin. 
These studied also reported that neither adrenomedullin nor PAMP had any effect 
on basal aldosterone secretion or ACTH-stimulated aldosterone secretion in the 
rat or basal aldosterone secretion in normal human adrenocortical cells (Andreis 
et al. 1997a; Andreis et al. 1998). In the present study PAMP also caused a 
dose-dependent, as well as time-dependent, increase in aldosterone secretion. As 
with adrenomedullin the stimulatory effect of PAMP on aldosterone secretion 
was also observed after 48 hour pre-treatment with All. However, PAMP had no 
effect on aldosterone secretion after 48 hour pre-treatment with forskolin. This 
would suggest that while adrenomedullin and PAMP have similar effects on 
aldosterone secretion they are acting through independent specific receptors, at 
least in the event of forskolin pre-treatment. Although the presence of specific 
PAMP binding sites have been reported, to date no PAMP receptors have been 
cloned. It may be that there are several PAMP receptors, at least one of which 
may also bind adrenomedullin, and that pre-treatment with forskolin alters the 
expression of these receptors, thus eliminating the stimulatory effect of PAMP on 
adrenomedullin secretion. 
ii. Effect on Glucocorticoid Secretion 
The reported effects of adrenomedullin on cortisol secretion have also been 
somewhat contradictory. Adrenomedullin has been shown to have no effect on 
cortisol secretion from dispersed human adrenocortical cell or from human 
adrenal slices (Andreis et al. 1997a). Neither was cortisol secretion altered in 
sheep with pacing-induced heart failure after IV administration of 
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adrenomedullin (Rademaker et al. 1997). Two other studies, in sheep, do report 
altered cortisol secretion, however one study reports a decrease in plasma cortisol 
after intracerebroventricular (ICV) infusion of adrenomedullin while the other 
reports an increase in plasma cortisol after ICV infusion of adrenomedullin 
(Parkes and May 1995; Charles et al. 1998). The data presented in this study 
show that both adrenomedullin and PAMP also stimulated cortisol secretion in a 
dose-dependent manner. No reports of increased glucocorticoid secretion in 
response to adrenomedullin have been reported in the rat despite a small number 
of adrenomedullin receptors being located in the inner zones (Kapas et al. 1998). 
The effect of adrenomedullin and PAMP in vivo, on secretion of steroid from the 
inner zones of the adrenal cortex has not been reported. Adrenomedullin and 
PAMP may act to increase transcription of one of the steroidogenic enzymes 
early in the pathway of steroidogenesis, thus giving rise to increased aldosterone 
secretion in vivo. However, in a pluripotent adrenocortical cell line such as the 
H295R cell line this would also result in an increase in secretion of other 
steroids. This could be the case as several steroidogenic enzymes are regulated 
by cAMP. 
iii. Effects on DHEA Secretion 
While adrenomedullin and PAMP had similar effects on aldosterone and cortisol 
secretion, there were differences in their effects on DHEA secretion. PAMP 
caused an increase in DHEA secretion but adrenomedullin did not. Therefore, it 
would appear likely that these two peptides mediate an increase in steroid 
secretion, at least in the event of DHEA secretion, via different mechanisms. 
PAMP-mediated increase in DHEA secretion is likely not to occur via a cAMP- 
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dependent mechanism as the increase in cAMP release observed in response to 
PAMP was of similar magnitude to that observed in response to adrcnomcdullin, 
yet DHEA secretion remained unaltered in response to adrenomcdullin. 
These data would suggest that PAMP is a novel stimulator of DHEA 
secretion, however, the mechanism by which this action of PAMP is achieved is 
unclear. 
h. Adrenomedullin Receptors 
The rtPCR data in this study revealed the expression of both L1 and CRLR and 
the CRLR accessory protein RAMP-2, but not RAMP-1. From the data 
presented in this study it is unclear as to which receptor adrenomedullin is acting 
through, although it is most probably not a CGRP receptor. In addition to the 
two candidate adrenomedullin receptors identified to date, L1 and CRLR (Kapas 
et al. 1995, Njuki et al. 1993), adrenomedullin is also known to bind to the 
CGRP receptor. In human adrenal glands adrenomedullin is thought to act 
through the CGRP receptor, as in previous studies adrenomedullin binding was 
displaced by the CGRP receptor antagonist CGRPg. 37 (Belloni et al. 1999). 
However, this is not the case in H295R cells as it is highly unlikely that CGRP 
receptors are expressed in this cell line as CGRP was without effect on 
aldosterone secretion. The presence of CGRP receptors was not directly 
investigated in this study other than to determine the presence of RAMP-1, which 
confers CGRP specificity to CRLR (McLatchie et al. 1998). RAMP-1 was not 
found to be present in H295R cells, suggesting that in this cell line CRLR only 
functions as an adrenomedullin receptor. This, taken together with the data from 
the steroid secretion, which showed that GCRP had no effect on steroid secretion 
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by the H295R cell line, would suggest that there are no CGRP receptors present 
in the H295R cell line. PCR for the CGRP receptor RDC1 was not carried out as 
a human sequence was not available. In human adrenal preparations CGRP has 
been shown to inhibit aldosterone secretion (Andreis et al. 1997). However, in 
H295R cells CGRP was entirely without effect on steroid secretion. Taken 
together these data would suggest that while the CGRP receptor is expressed in 
human adrenals the H295R cell line does not express functional CGRP receptors. 
This would suggest that the H295R cell line would be a useful tool in the further 
study of adrenomedullin receptors. 
Of the other two receptors known to bind adrenomedullin, L1 and CRLR, 
both were found to be expressed in H295R cells. In addition to CRLR the 
receptor activity modifying protein, RAMP-2, required to confer adrenomedullin 
specificity to CRLR (McLatchie et al. 1998) was also shown to be expressed. 
Therefore, while these cells express both candidate adrenomedullin receptors it 
remains unclear as to which receptor adrenomedullin is acting through. 
However, pre-treatment of the H295R cells with adrenomedullin, PAMP, All or 
forskolin did not appear to alter L1 receptor expression. This would suggest that 
in the H295R cell line, L1 may either be constitutively expressed or that it is 
regulated by some mechanism other than adrenomedullin itself or cAMP. CRLR 
expression however, does appear to be actively regulated. Pre-treatment with 
forskolin greatly reduced expression of CRLR while pre-treatment with All did 
not. This may indicate that CRLR is associated with a zona glomerulosa 
phenotype rather than a zonae fasciculata/ reticularis phenotype. As 
adrenomedullin was still able to stimulate aldosterone and cortisol secretion after 
48 hour pre-treatment with forskolin it is likely that adrenomedullin is acting 
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through the LI receptor as expression of CRLR after forskolin pre-treatment was 
greatly decreased. However, while the level to which adrenomedullin stimulated 
cortisol secretion was similar after both All and forskolin pre-treatments and also 
when no pre-treatment had been administered the same was not true for 
aldosterone secretion. Aldosterone secretion in response to adrenomedullin was 
2- to 3-fold greater after All pre-treatment than with no pre-treatment or 
forskolin pre-treatment. This would suggest that in terms of aldosterone 
secretion adrenomedullin may be acting through the CRLR/ RAMP-2 complex. 
RAMP-2 however was not similarly affected, being expressed after both All and 
forskolin pre-treatment. This may suggest that regulation of receptor activity is 
via CRLR itself and not the associated RAMP's. Interestingly, pre-treatment of 
H295R cells with PAMP completely knocked out expression of CRLR and also 
reduced expression of RAMP-2. This is somewhat unexpected as PAMP does 
not bind to the CRLR/ RAMP-2 complex. It may be that expression of RAM P's 
is dependent on expression of CRLR and that in the event of down regulation of 
CRLR, the associated RAMP's are also down regulated. This may explain why 
RAMP-2 is still expressed after forskolin pre-treatment, as the effect of forskolin 
pre-treatment was not as intense as that of PAMP. It may be that CRLR 
expression is inhibited by cAMP, thus explaining the effect of PAMP and 
forskolin. If this were the case then it would be expected that adrenomedullin 
would also inhibit expression of CRLR through generation of cAMP. This 
would however not account for expression of CRLR after pre-treatment with 
adrenomedullin as adrenomedullin also causes an increase in cAMP. However, it 
may be that expression of CRLR is also dependent on adrenomedullin, which is 
also inhibited by cAMP, and addition of exogenous adrenomedullin sustains 
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receptor expression. There is however as yet no evidence to support this theory. 
Another possibility for the apparent regulation of CRLR by PAMP is that CRLR 
can also act as a receptor for PAMP when complexed to some as yet unidentified 
RAMP. As far as can be determined, to date there are no reported studies on the 
regulation of either L1 or CRLR. Further study into this area could determine the 




In conclusion, these studies have shown that in the rat PAMP acts to stimulate 
aldosterone secretion via cAMP-dependent mechanism in intact adrenal capsules. 
The same effects however are not observed in collagenase dispersed zona 
glomerulosa cells, suggesting that intraglandular signal transduction mechanisms 
may be involved. This effect could be further studied by analysing cAMP 
release from endothelial cells, as this cell type is abundant in the adrenal and 
could be contributing to the observed increase in cAMP secretion in both tissue 
preparations used. It is also possible that PAMP, like adrenomedullin, can 
operate via more than one signalling pathway. Calcium mobilisation could be 
determined by loading the cells with fura-2. 
The data presented also revealed the presence of two populations of 
PAMP binding sites in the rat zona glomerulosa. It is likely that these two 
populations represent separate receptors as adrenomedullin displaced PAMP 
binding at only one of the sites. Further receptor binding studies could be 
conducted to provide more information about PAMP binding as currently no 
IAP, 
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PAMP receptor has been identified or cloned. As based on the data presented in 
this study it is likely that at least one, if not two PAMP receptors exist, one of 
which may also bind adrenomedullin. 
Data presented in this study from the human adrenocortical H295R cell line 
showed that AM and PAMP are expressed in H295R cells and that the mature 
peptides are secreted. Secretion of the two peptides was not equimolar and their 
expression did not appear to be constant. To determine if the stimulatory effects 
of All and forskolin were direct or mediated in part by the corresponding 
increase in steroidogenesis an inhibitor of steroidogenesis, such as 
aminoglutethimide an inhibitor of cholesterol side chain cleavage or using 
specific receptor antagonists, spironolactone for aldosterone and RU486 for 
cortisol, could be used. Also as the PCR carried out in this study was not 
quantitative, real time PCR or Northern Blot analysis could be carried out to 
confirm the findings of this study. The main area of future work would surround 
the transcriptional regulation of the adrenomedullin gene. Data from this study 
suggested that adrenomedullin and PAMP may be actively regulated and 
expression studies could be conducted further investigate this. A direct study 
could also be carried out to determine if adrenomedullin and PAMP are self 
regulating, as is suggested by the PCR analysis of exons 2 to 3 (PAMP) and 
exon 4 (AM) of the adrenomedullin gene. This could be tested by treating 
H295R cells with Ca2+ blockers and activators/stimulators and measuring the 
expression of adrenomedullin, as adrenomedullin has also been shown to operate 
via Ca2+ mobilisation. 
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Immunocytochemistry studies could be repeated on 11295R cells which 
had been treated with All and forskolin to determine if staining or intensity of 
staining altered. This data would support finding from EIA and PCR in this 
study. 
While binding studies for both PAMP and adrenomedullin were carried 
out on H295R cells no data was obtained and these studies could be repeated 
under different conditions to determine PAMP and adrenomedullin binding in 
H295R cells, as data presented in this study from PCR analysis shows that 
CRLR is present in this cell line. To try and determine which receptor, either the 
CRLR/RAMP-2 complex or L1, adrenomedullin as acting through, cells could 
be incubated in the presence of CRLR or L1 antibody and then steroidogenesis 
in response to adrenomedullin could be measured. Additionally the signalling 
mechanisms by which adrenomedullin and PAMP operate could be investigated 
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